
==== Front
Eur J Med Res
Eur J Med Res
European Journal of Medical Research
0949-2321
2047-783X
BioMed Central London

39218950
2033
10.1186/s40001-024-02033-w
Review
Role of the lncRNA/Wnt signaling pathway in digestive system cancer: a literature review
Li Penghui lph0819@163.com

1
Ma Xiao 2
Huang Di 3
1 https://ror.org/05d80kz58 grid.453074.1 0000 0000 9797 0900 Department of Gastrointestinal Surgery, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, 471000 Henan China
2 https://ror.org/059cjpv64 grid.412465.0 Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
3 https://ror.org/039nw9e11 grid.412719.8 Department of Child Health Care, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 Henan China
2 9 2024
2 9 2024
2024
29 44724 3 2024
21 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
The long noncoding RNA (lncRNA)/Wingless (Wnt) axis is often dysregulated in digestive system tumors impacting critical cellular processes. Abnormal expression of specific Wnt-related lncRNAs such as LINC01606 (promotes motility), SLCO4A1-AS1 (promotes motility), and SH3BP5-AS1 (induces chemoresistance), plays a crucial role in these malignancies. These lncRNAs are promising targets for cancer diagnosis and therapy, offering new treatment perspectives. The lncRNAs, NEF and GASL1, differentially expressed in plasma show diagnostic potential for esophageal squamous cell carcinoma and gastric cancer, respectively. Additionally, Wnt pathway inhibitors like XAV-939 have demonstrated preclinical efficacy, underscoring their therapeutic potential. This review comprehensively analyzes the lncRNA/Wnt axis, highlighting its impact on cell proliferation, motility, and chemoresistance. By elucidating the complex molecular mechanisms of the lncRNA/Wnt axis, we aim to identify potential therapeutic targets for digestive system tumors to pave the way for the development of targeted treatment strategies.

Keywords

LncRNA
Wnt pathway
Digestive system tumors
Diagnosis
Therapeutic targets
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Digestive system cancers, including esophageal, gastric, liver, colorectal, and pancreatic cancers, constitute a significant proportion of global cancer incidence and mortality, imposing a substantial burden on global public health [1]. These tumors often remain undetected until advanced stages, leading to diminished prognosis and survival rates. Despite extensive research, the pathogenesis of most digestive system cancers remains poorly understood, and viable treatment options are limited. This presents a formidable challenge in developing targeted therapies.

Long noncoding RNA (lncRNA), devoid of protein-coding potential, can interact with microRNA (miRNA) or RNA-binding proteins, influencing the biological activity of downstream signaling pathways [2–5]. Thanks to RNA sequencing technology and bioinformatics tools, lncRNAs were found to be involved in cellular processes such as cell proliferation, transcriptional regulation, and signal transduction [6–9]. Recent findings have shown that long noncoding RNAs (lncRNAs) exhibit various expression patterns and have multiple functions. As a result, they play a crucial role in ongoing biomedical research. Recently, research on lncRNAs has expanded to include digestive system tumors. Abnormal lncRNA expression in these tumors is associated with crucial oncogenic processes, including uncontrolled cell proliferation, enhanced invasion, and increased metastatic potential [10, 11].lncRNAs affect tumor development by regulating gene expression and signal pathways [12–14]. Notably, lncRNAs’ involvement in the Wingless (Wnt)/β-catenin signaling pathway, which regulates normal physiological processes, has been identified as a significant factor in the progression of various digestive system cancers [15, 16]. Certain lncRNAs such as lncRNA GASL1, lncRNA MEG3, and NEF, can interact with genes linked to the Wnt pathway and modulate the transmission and activity of Wnt signals in digestive system tumors [17–19]. This regulatory effect may be achieved through various mechanisms. LncRNAs can act as miRNA sponges, which modulates the targeted regulation of Wnt pathway-related genes. For instance, lncRNA PART1 functions as a competitive endogenous RNA (ceRNA) in colorectal cancer, sequestering miR-150-5p and miR-520 h, resulting in the upregulated expression of CTNNB1 and the activation of the Wnt/β-catenin pathway [20]. Dysregulation of these mechanisms may lead to abnormal Wnt pathway activation, contributing to the development of digestive system tumors. This review focuses on understanding the roles and molecular mechanisms of long noncoding RNAs (lncRNAs) associated with the Wnt pathway in digestive system tumors. By gaining deeper insights into these mechanisms, we aim to identify potential lncRNA targets for therapeutic intervention.

lncRNA and Wnt signaling pathway

Significance of the Wnt pathway

The Wingless (Wnt) gene was first identified through random mutagenesis screening of fruit flies (Drosophila melanogaster) [21, 22]. Mutations in the Wnt gene inhibited wing development and created abnormal larval segmentation in fruit flies. The Wnt protein, forms a complex with Frizzled receptors and the low-density-lipoprotein receptor-related protein (LRP) to regulate β-catenin activity within cells, which influences processes such as cell proliferation, differentiation, and directional migration [23–26]. The Wnt signaling pathway comprises two distinct intracellular signaling pathways: the canonical and noncanonical Wnt pathway. The noncanonical Wnt pathway includes, Ca2+ pathway, and planar cell polarity (PCP) pathway [27, 28].

In the canonical Wnt pathway, Wnt signals primarily activate the Frizzled receptor-LDL receptor-related proteins (LRPs) complex [29, 30]. Wnt ligand binding leads to the stabilization and nuclear translocation of β-catenin [31]. In the absence of Wnt signaling, glycogen synthase kinase 3beta (GSK3beta) and other kinases phosphorylate β-catenin, marking it degradation, thus maintaining a low basal level of β-catenin in the cytoplasm [32, 33]. When the Wnt ligand binds to the Frizzled receptor and LRP complex, the complex undergoes a conformational change, ultimately activating the Frizzled receptor. This triggers a cascade of signaling events, including the inhibition of GSK3β phosphorylation and the release of Axin, which results in the accumulation of unphosphorylated and stable β-catenin in the cytoplasm. Stabilized β-catenin translocate into the nucleus and interacts and activates the T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors [34, 35]. This, in turn, promotes the expression of specific genes involved in regulating cell proliferation, differentiation, and survival.

Dysregulation of Wnt signaling in digestive system tumors

Aberrant Wnt signaling is a hallmark of many digestive system cancers, including colorectal cancer, gastric cancer, hepatocellular carcinoma (HCC), and pancreatic cancer [16, 36–38]. Mutations in key Wnt pathway components, such as β-catenin, and Axin, often lead to constitutive activation of Wnt signaling, resulting in uncontrolled cellular proliferation and survival, thereby contributing to tumorigenesis and cancer progression [16, 39, 40]. In colorectal cancer, mutations in the adenomatous polyposis coli (APC) gene are common, causing nuclear accumulation of β-catenin and subsequent activation of oncogenic Wnt target genes [41]. Similar mutations in β-catenin prevent its degradation, sustaining an activated Wnt signaling, which disrupts normal gastrointestinal homeostasis. These alterations in β-catenin and APC are commonly observed in gastric cancer [42]. Additionally, hypermethylation of Wnt antagonist genes like secreted frizzled-related protein (SFRP) and Dickkopf (DKK) reduces the inhibition of Wnt signaling [43, 44]. High levels of nuclear β-catenin in gastric cancer correlate with poor prognosis and advanced stages of the disease, suggesting a role in tumor aggressiveness and metastasis [45–47]. In HCC, prevalent mutations in CTNNB1 (encoding β-catenin) stabilize β-catenin, promoting transcription of genes that support cell proliferation and survival [48, 49]. Epigenetic alterations, such as promoter hypermethylation of Wnt suppressors, such as SFRP1 and DKK1, further contribute to enhanced Wnt signaling in HCC, which promotes, cell invasion, and tumor growth [50–54]. While mutations in Wnt pathway components are less common in pancreatic cancer, upregulation of Wnt ligands and receptors is frequently observed, which is sufficient to sustain Wnt signaling and contribute to cancer stem cell maintenance [55, 56]. Wnt signaling interacts with other pathways, such as Hedgehog and Notch, creating a complex network that drives pancreatic tumor growth and metastasis.

Comprehensive overview of lncRNAs

Initially considered transcriptional noise due to their lack of protein-coding potential [57, 58], long noncoding RNAs (lncRNAs) have emerged as key regulators of gene expression [59], thanks to advancements in high-throughput sequencing technologies. LncRNAs are RNA molecules, exceeding 200 nucleotides in length, characterized by their inability to code for proteins. They are classified based on their genomic location relative to protein-coding genes [60, 61]. The biogenesis of lncRNAs involves transcription by RNA polymerase II, including the addition of a 5' cap and polyadenylation at the 3' end, like messenger RNAs (mRNAs) [62, 63]. LncRNAs also undergo splicing, although the mechanisms can highly vary compared to mRNAs. These RNAs can be transcribed from various genomic loci, including intergenic regions, introns, and promoters of protein-coding genes. The primary categories include intergenic lncRNAs, intronic lncRNAs, sense lncRNAs, antisense lncRNAs, and bidirectional lncRNAs. Unlike mRNA, which carries the genetic code for protein synthesis, lncRNAs are involved in a diverse range of cellular processes [64]. By interacting with miRNAs, RNA-binding proteins, and other components of cellular machinery, lncRNAs regulate gene expression, eventually impacting various downstream signaling pathways [65–67]. The study of lncRNAs has provided significant insights into the complexities of gene regulation, revealing their crucial roles in cellular function and diseases, such as cancer, cardiovascular disorders, and neurological disorders [68–70]. In the context of cancer, lncRNAs can function as oncogenes or tumor suppressors, influencing various aspects of tumor biology. Understanding the roles of lncRNAs could lead to novel therapeutic strategies for treating these malignancies. LncRNAs affects the development of digestive system tumors by regulating gene expression and signal pathway activity. Abnormal expression of lncRNAs in these tumors is closely linked to key biological functions such as cell proliferation, invasion, and metastasis [71]. The expression levels of certain lncRNAs are either significantly upregulated or downregulated in digestive system tumor tissues, correlating with clinical features such as tumor grade, prognosis, and treatment response [72].

The crucial role of the lncRNA/Wnt axis in digestive system tumors

Dysregulation of the lncRNA/Wnt axis affects cell self-renewal and differentiation properties of cancer stem cells, as well as tumor cell proliferation, survival, and invasion. The lncRNA/Wnt axis also promotes epithelial–mesenchymal transition (EMT), tumor metastasis capabilities, and resistance to apoptosis. Additionally, lncRNAs modulate the expression of genes within the Wnt signaling pathway related to drug resistance, thereby reducing tumor sensitivity to chemotherapeutic agents. Consequently, extensive research is dedicated to targeting the lncRNA/Wnt axis to formulate effective therapeutic strategies for digestive system tumors. Understanding the lncRNA/Wnt axis dynamics can revolutionize patient management by identifying new therapeutic avenues for digestive system tumors.

Wnt pathway-associated lncRNAs in digestive system cancer

Esophageal cancer

Role of Wnt pathway-associated lncRNAs in promoting esophageal cancer

In esophageal squamous cell carcinoma (ESCC), the lncRNAs MYU, HERES, SNHG16, HOTAIR, and DGCR5 are notably upregulated (Fig. 1) [73–77]. These lncRNAs interact with the Wnt signaling pathway, playing significant roles in cancer progression. Overexpression of lncRNA MYU is linked to advanced clinicopathological features including higher histopathological grade, tumor invasion severity, lymph node metastasis, and advanced TNM stage in esophageal cancer patients (Table 1) [73]. Similarly, SNHG16 expression correlates with advanced tumor stage, lymph node metastasis, while HOTAIR expression is associated with higher histologic grade and nodal status in ESCC patients [75, 76]. Elevated DGCR5-S levels are connected to tumor recurrence, larger tumor size, lymph node metastasis, and advanced clinical stages in ESCC [78]. High expression levels of these lncRNAs (MYU, HERES, SNHG16, HOTAIR, and DGCR5-S) predict poorer prognosis, with HERES expression particularly reducing stage-free survival rates [73–75]. Functionally, lncRNA MYU and HERES promoted cell proliferation, migration, and invasion in ESCC cells, while HOTAIR specifically enhanced migration and invasion capabilities (Table 2) [73, 74, 76]. DGCR5-S promotes tumor aggression by encouraging macrophage infiltration, increasing cancer-associated fibroblasts, and stimulating angiogenesis [77]. Reducing lncRNA MYU expression leads to smaller tumors in nude mice and lower Ki-67 levels, indicating its role in tumor growth [73]. LncRNA MYU regulates the Wnt/β-catenin signaling pathway; its downregulation decreases the expression of key molecules like Wnt, β-catenin, and c-Myc, thereby attenuating oncogenic effects (Fig. 2) [73]. The Wnt/β-catenin pathway agonist CT99021 can counteract the oncogenic effects of lncRNA, such as tumor invasion [73]. HERES activates Wnt signaling through interaction with EZH2 through a G-quadruplex structure-like motif [74]. LncRNA MYU promotes cell invasion through the activation of the Wnt/β-catenin signaling pathway. HOTAIR exerts a direct inhibitory effect on WIF-1 expression by facilitating histone H3K27 methylation in the promoter region, consequently activating the Wnt/β-catenin signaling pathway [76]. DGCR5S increases metastatic potential by stimulating Wnt/β-catenin signaling through a splicing switch induced by Wnt3a, generating a shorter variant called DGCR5-S [79], which also promotes angiogenesis and macrophage infiltration. Targeting the Wnt/β-catenin signaling pathway effectively downregulates DGCR5-S expression, thereby suppressing ESCC progression [79].Fig. 1 Wnt pathway-associated lncRNAs in digestive system tumors

Table 1 Expression and clinical characteristics of the lncRNA/Wnt axis in digestive system tumors

Type	lncRNA	Expression	Features	Refs.	
Esophageal cancer	lncRNA MYU	Upregulated	Histopathological grade, clinical stage, prognosis	[73]	
Esophageal cancer	HERES	Upregulated	Prognosis	[74]	
Esophageal cancer	SNHG16	Upregulated	Tumor stage, lymph node metastasis, clinical stage, prognosis	[75]	
Esophageal cancer	HOTAIR	Upregulated	Histologic grade, nodal status, metastasis, prognosis	[76]	
Esophageal cancer	DGCR5	Upregulated	Tumor relapse, tumor size, lymph node metastasis, clinical stages, prognosis	[77]	
Esophageal cancer	lncRNA GASL1	Downregulated		[17]	
Esophageal cancer	lncRNA MEG3	Downregulated	Tumor size, lymph node metastasis, clinical stage, prognosis	[18]	
Esophageal cancer	lncRNA NEF	Downregulated	Tumor size, tumor distant metastasis, prognosis	[19]	
Gastric cancer	SNHG11	Upregulated	Advanced stage, metastasis, prognosis	[46]	
Gastric cancer	lncRNA HOXC-AS1	Upregulated		[85]	
Gastric cancer	ZEB2-AS1	Upregulated		[81]	
Gastric cancer	ZEB2-AS1	Upregulated		[82]	
Gastric cancer	H19	Upregulated	Histologic grade, prognosis	[83]	
Gastric cancer	LINC01226	Upregulated	Prognosis	[84]	
Gastric cancer	LINC01133	Downregulated	Tumor size, T stage, lymphatic invasion, TNM stage, infiltration of peritumoral tissues, prognosis	[87]	
Gastric cancer	GASL1	Downregulated	Postoperative survival time	[88]	
Liver cancer	PRR34-AS1	Upregulated		[93]	
Liver cancer	SNHG5	Upregulated	Tumor size, hepatitis B virus infection, histologic grade, TNM stage, portal vein tumor thrombus, prognosis	[8, 89]	
Liver cancer	lncRNA-DAW	Upregulated		[94]	
Liver cancer	FOXD2-AS1	Upregulated	Prognosis	[91]	
Liver cancer	CTB-193M12.5	Upregulated	Alpha-fetoprotein, tumor size, clinical characteristics, prognosis	[92]	
Liver cancer	lncRNA-CR594175	Upregulated	Metastasis	[90]	
Liver cancer	lncRNA-MUF	Upregulated		[95]	
Liver cancer	KB-68A7.1	Downregulated	Tumor size, clinical characteristics, prognosis	[96]	
Liver cancer	lncRNA-NEF	Downregulated		[97]	
Colorectal cancer	STEAP3-AS1	Upregulated	Prognosis	[98]	
Colorectal cancer	MIR100HG	Upregulated	Lymph node metastasis, distant metastasis	[108]	
Colorectal cancer	MIR100HG	Upregulated		[99]	
Colorectal cancer	LEF1-AS1	Upregulated		[100]	
Colorectal cancer	PART1	Upregulated		[20]	
Colorectal cancer	LINC01606	Upregulated	Depth of invasion, lymph node metastasis, stage, prognosis	[101]	
Colorectal cancer	H19	Upregulated	Prognosis	[102]	
Colorectal cancer	SLCO4A1-AS1	Upregulated	Clinical grade, prognosis	[103]	
Colorectal cancer	AC010789.1	Upregulated	Lymph node metastasis, prognosis	[104]	
Colorectal cancer	CRNDE	Upregulated	Prognosis	[105]	
Colorectal cancer	HOTAIR	Upregulated	Prognosis	[106]	
Pancreatic cancer	PVT1	Upregulated		[110]	
Pancreatic cancer	SH3BP5-AS1	Upregulated	Prognosis	[111]	
Pancreatic cancer	LINC01614	Upregulated	Prognosis	[112]	
Pancreatic cancer	OIP5-AS1	Upregulated		[113]	
Pancreatic cancer	FAM83H-AS1	Upregulated	Prognosis	[114]	
Pancreatic cancer	LINC01197	Downregulated	Prognosis	[115]	

Table 2 Function and mechanism of the lncRNA/Wnt axis in digestive system tumors

Type	lncRNA	Role	In vitro	Experimental model	Function	Related genes	Refs.	
Esophageal cancer	lncRNA MYU	Oncogenic	Eca109, Kyse150, TE-1, TE-13, and het-1A	Four-week-old female BALB/C nude mice	Cell proliferation, migration, and invasion	Wnt, β-catenin	[73]	
Esophageal cancer	HERES	Oncogenic	KYSE-30, and HCE-7 cell	Six-week-old male BALB/c nude mice	Cell proliferation, migration, invasion, and colony formation	EZH2, Wnt, β-catenin	[74]	
Esophageal cancer	SNHG16	Oncogenic	TE-13, TE-1, EC-1, Eca-109, and HEEC			Wnt, β-catenin	[75]	
Esophageal cancer	HOTAIR	Oncogenic	KYSE30, KYSE140, KYSE180, KYSE410, and KYSE510		Cell migration, and invasion	WIF‐1, Wnt, β-catenin	[76]	
Esophageal cancer	DGCR5	Oncogenic	KYSE140, KYSE180, KYSE520, KYSE510, KYSE450, KYSE30, KYSE410, KYSE180, KYSE150, THP-1, WI-38, and 293 T	Four- to five-week-old immune-deficient BALB/c-nude mice, C57BL/6, and NOD-SCID (nonobese diabetic-severe combined immunodeficiency	Inflammation, and tumor growth	TTP, Wnt3a, β-catenin	[77]	
Esophageal cancer	lncRNA GASL1	Tumor suppressor	TE-1, ECA-109, KYSE-410, KYSE-5200, and KYSE-150	Four-week-old female BALB/c mice	Cell proliferation, invasion, and migration	DKK1, Wnt3a, β-catenin	[17]	
Esophageal cancer	lncRNA MEG3	Tumor suppressor	EC109, EC9706, KYSE150, KYSE450, and KYSE510	Four-week-old athymic female BALB/c mice	Cell proliferation, migration and invasion	miR-4261, DKK2, Wnt, β-catenin	[18]	
Esophageal cancer	lncRNA NEF	Tumor suppressor	KYSE510, and EC9706		Cell proliferation, migration and invasion	Wnt, β-catenin	[19]	
Gastric cancer	SNHG11	Oncogenic	SGC7901, BGC823, MGC-803, MKN45, HGC27, and AGS	Four- to six-week-old male BALB/c nude mice	Cell proliferation, stemness, migration, invasion	miR-483-3p, miR-1276, CTNNB1, CUL4A, Wnt, β-catenin	[46]	
Gastric cancer	lncRNA HOXC-AS1	Oncogenic	AGS, MKN45, MKN28, and HGC-27		Cell viability, epithelial–mesenchymal transition, and apoptosis	eIf4AIII, Wnt, β-catenin	[85]	
Gastric cancer	ZEB2-AS1	Oncogenic	SGC-7901, BGC-823, and MKN45	Five-week-old female athymic BALB/c mice	Cell proliferation, migration, invasion, and apoptosis	ZEB2, Wnt, β-catenin	[81]	
Gastric cancer	ZEB2-AS1	Oncogenic	SGC7901		Cell migration, invasion, epithelial–mesenchymal transition, and chemotherapeutic tolerance	Wnt, β-catenin	[82]	
Gastric cancer	H19	Oncogenic	GES-1, AGS, MGC-803, SGC-7901, and BGC-823	Four/six-week-old BALB/c nude mice	Epithelial–mesenchymal transition and metastasis	Wnt, β-catenin	[83]	
Gastric cancer	LINC01226	Oncogenic	MGC80-3, and HEK293T	Five-week-old female nude BALB/c mice	Cell proliferation, migration and invasion	STIP1-HSP90, Wnt, β-catenin	[84]	
Gastric cancer	LINC01133	Tumor suppressor	SUN-216, BGC-823, AGS, BGC-803, NUGC4, MKN74, MKN45, SGC-7901, and HGC-27	Four-week-old immunodeficient BABL/c female nude mice	Cell proliferation, migration, and epithelial–mesenchymal transition	miR-106a-3p, Wnt, β-catenin	[87]	
Gastric cancer	GASL1	Tumor suppressor	SNU-16, and NCI-N87		Cell proliferation	Wnt, β-catenin	[88]	
Liver cancer	PRR34-AS1	Oncogenic	Hep 3B, SK-HEP-1, Huh7, HCCLM3, and MHCC97-H	Male BALB/C nude mice	Cell proliferation, migration, invasion, and epithelial–mesenchymal transition	miR-296-5p, E2F2, SOX12, Wnt, β-catenin	[93]	
Liver cancer	SNHG5	Oncogenic	HepG2, Huh7, Hep3B, HepG2, SMCC-7721, MHCC-97L, MHCC-97H, Huh7, and LO2	Four-week-old BALB/c nude mice, four-week-old male athymic BALB/c nude mice	Cell proliferation and CSC-like properties	UPF1, Wnt, β-catenin	[8]	
Liver cancer	lncRNA-DAW	Oncogenic	HEK293T, B16-F10, LO2, Hep3B, Huh7, HepG2, and PLC/PRF/5	C57BL/6 mice	Cell proliferation, and colony formation	EZH2, Wnt2, β-catenin	[94]	
Liver cancer	FOXD2-AS1	Oncogenic	HepG2, Hep3B, SMMC-7721, and LM3		Cell proliferation, apoptosis, migration, and epithelial–mesenchymal transition	EGR1, DKK1, Wnt, β-catenin	[91]	
Liver cancer	CTB-193M12.5	Oncogenic	THLE-3, SK-HEP-1, SNU-398, and HuH-7		Cell proliferation, cell apoptosis, cell migration and invasion	WNT10B, β-catenin	[92]	
Liver cancer	lncRNA-CR594175	Oncogenic	HepG2, and 293TN	Female athymic nude mice	Cell proliferation, and invasion	miR-142-3p, CTNNB1	[90]	
Liver cancer	lncRNA-MUF	Oncogenic	293 T, Hep3B, and PLC, Huh7, HepG2, MHCC-97L, HCC-LM3, and SMMC-7721		Epithelial–mesenchymal transition	miR-34a, ANXA2, Wnt, β-catenin	[95]	
Liver cancer	KB-68A7.1	Tumor suppressor	THLE-3, SNU-398, and SK-HEP-1	Five-week-old male athymic BALB/c nude mice	Cell proliferation, apoptosis, cell migration, and invasion	NSD1, WNT10B, β-catenin	[96]	
Liver cancer	lncRNA-NEF	Tumor suppressor	HEK293T	Nude BALB/c mice	Epithelial–mesenchymal transition, and cell migration	FOXA2, Wnt, β-catenin	[97]	
Colorectal cancer	STEAP3-AS1	Oncogenic	HCT116, RKO, DLD-1, LoVo, SW480, SW620, and HT29	Six- to eight-week-old male BALB/c nu/nu mice	Cell proliferation, migration, and invasion	STEAP3, YTHDF2, Wnt, β-catenin	[98]	
Colorectal cancer	MIR100HG	Oncogenic	NCI-H508, Caco-2, SW403, SW948, HT29, SK-CO-1, DLD-1, SW480, SW837, SW48, SW620, LoVo, COLO205, T84, LS174T, NCIH716, HCT8, HCT15, SW1116, RKO, COLO320DM, HuTu80, and LS123 HCT116, DiFi, GEO, LIM1215, LIM2405, V9P, HCA-7	Six- to eight-week-old female athymic BALB/c nude mice	Epithelial–mesenchymal transition, cetuximab resistance, invasion, and metastasis	TCF7L2, hnRNPA2B1, Wnt, β-catenin	[108]	
Colorectal cancer	MIR100HG	Oncogenic	NCI-H508, Caco-2, SW403, SW948, HT29, SK-CO-1, DLD-1, SW480, SW837, SW48, SW620, LoVo, COLO205, T84, LS174T, NCI-H716, HCT8, HCT15, SW1116, RKO, COLO320DM, HuTu80, LS123, HCT116, HCA-7, and SNUC4	Six- to eight-week-old female athymic BALB/c nude mice	Cetuximab responsiveness	miR-100, miR-125b, Wnt, β-catenin	[99]	
Colorectal cancer	LEF1-AS1	Oncogenic	HCT-8, Caco2, SW480, SW620, and LOVO	Four- to five-week-old male nude mice	Cell proliferation, migration, and invasion	LEF1, FUT8, Wnt, β-catenin, LEF1	[100]	
Colorectal cancer	PART1	Oncogenic	HCT-116, SW116, SW480, and HT29	Four- to five-week-old BALB/c nude mice	Cell proliferation, invasion, migration, and cell apoptosis	miR-150-5p, miR-520 h, CTNNB1, Wnt, β-catenin	[20]	
Colorectal cancer	LINC01606	Oncogenic	W480, and HT29	Four‐week‐old female nude mice	Cell growth, invasion, and stemness	SCD1–Wnt, β‐catenin, TFE3	[101]	
Colorectal cancer	H19	Oncogenic	HCT116, HT-29, SW620, and SW480		Cell proliferation, and cell invasion	miR-29b-3p, PGRN, Wnt, β-catenin	[102]	
Colorectal cancer	SLCO4A1-AS1	Oncogenic	HCT116, HCT8, HT29, SW480, LOVO, and SW620	Five-week-old athymic nude BALB/c mice	Cell proliferation, migration, invasion, epithelial–mesenchymal transition, and cell apoptosis	β-catenin	[103]	
Colorectal cancer	AC010789.1	Oncogenic	HCT116, SW1116, SW480, HT29, and DLD1	Twelve-five-week-old male BALB/c nude mice	Cell proliferation, migration, invasion, and epithelial–mesenchymal transition	miR-432-3p, ZEB1, Wnt, β-catenin	[104]	
Colorectal cancer	CRNDE	Oncogenic	HCT116, and SW480		Cell proliferation, and chemoresistance	miR-181a-5p, Wnt, β-catenin	[105]	
Colorectal cancer	HOTAIR	Oncogenic	CCD18Co, HCT15, CoLo205, HT29, DLD-1, and SW620		Cell proliferation, and chemoresistance	miR-203a-3p, Wnt, β-catenin	[106]	
Pancreatic cancer	PVT1	Oncogenic	PANC-1, ASPC-1, SW1990, and PANC-1	Four-week-old male BALB/c nude mice	Sensitivity to gemcitabine	miR-619-5p, Pygo2, miR-619-5p, ATG14	[110]	
Pancreatic cancer	SH3BP5-AS1	Oncogenic	AsPC-1, CFPAC-1, Capan-1, SW1990, PANC-1, SW1990, BxPC-3, and MIA-PaCa-2	Six-week-old male BALB/c nude mice	Cell migration, invasion, and sensitivity to gemcitabine	miR-139-5p, Wnt, β-catenin	[111]	
Pancreatic cancer	linc01614	Oncogenic	Panc-1, SW1990, BXPC-3, and MIA-PaCa	Four-week-old male BALB/c-nu mice	Cell proliferation, migration, and invasion	GSK-3β, AXIN1, β-catenin	[112]	
Pancreatic cancer	OIP5-AS1	Oncogenic	SW1990, CAPAN-1, BxPC-3, and PANC-1		Cell proliferation, migration, invasion, and apoptosis	FOXM1, Wnt, β-catenin	[113]	
Pancreatic cancer	FAM83H-AS1	Oncogenic	MIA PaCa-2, PANC-1, SW 1990, Capan-2, BxPC-3, CFPAC-1, Panc 03.27, and HPDE	Four/five weeks female BALB/c nude mice	Cell proliferation, invasion and metastasis	FAM83H, β-catenin	[114]	
Pancreatic cancer	LINC01197	Tumor suppressor	HPNE, AsPC1, BxPC3, and PANC1	BALB/c (nu/nu) mice	Cell proliferation	TCF4, β-catenin	[115]	

Fig. 2 lncRNAs exert a critical influence by modulating the Wnt pathway in esophageal cancer. On the one hand, molecules involved in the Wnt/β-catenin signaling pathway, including Wnt, β-catenin, and c-Myc, showed significantly downregulated expression following MYU downregulation. HERES triggers the Wnt signaling pathway by engaging EZH2 in esophageal cancer. HOTAIR inhibits WIF-1 to activate Wnt/β-catenin signaling through the PRC2 complex. Targeting Wnt/β-catenin signaling can downregulate DGCR5-S expression and suppress ESCC progression. On the other hand, MEG3 interacts with miR-4261, reducing DKK2 and blocking Wnt/β-cat signaling. NEF inhibits the onset of the cellular malignant phenotype by inactivating Wnt/β-cat signaling. The Wnt pathway-associated lncRNA GASL1 suppresses esophageal cancer progression by upregulating DKK1 expression

Role of Wnt pathway-associated lncRNAs in suppressing esophageal cancer

In ESCC cell lines, the expression of lncRNAs GASL1, lncRNA MEG3, and NEF is downregulated [17–19]. MEG3 expression negatively correlates with tumor size, lymph node metastasis, and clinical stage in ESCC [18]. NEF upregulation in serum significantly associates with tumor size and distant metastasis [19]. Overexpression of GASL1, MEG3, and NEF suppresses cell proliferation, migration, and invasion in esophageal cancer [17–19]. GASL1 overexpression notably arrests ESCC cells in the G0/G1 phase while reducing the S phase cell population and inhibiting tumor growth in vivo [17]. Mechanistically, the inhibition of DKK1 enhances Wnt3a/β-catenin signaling, counteracting GASL1’s suppressive effects on cellular functions (Fig. 2) [17]. The interaction between DKK1 and GASL1 is critical in in modulating these biological processes [17]. MEG3 interacts with miR-4261, leading to the suppression of the Wnt/β signaling inhibitor, Dickkopf-2 (DKK2), and subsequent blockade of the Wnt/β-catenin signaling pathway [18]. Wnt activator administration does not significantly affect NEF, but a Wnt inhibitor effectively diminishes NEF's impact on key cellular processes [19]. These findings suggest that inhibiting Wnt signaling can counteract NEF dysregulation, underscoring its potential therapeutic significance [19].

Gastric cancer

Role of Wnt pathway-associated lncRNAs in promoting gastric cancer

The expression levels of SNHG11, lncRNA HOXC-AS1, ZEB2-AS1, H19, and LINC01226 are significantly elevated in gastric cancer tissues and cell lines [46, 80–84]. Elevated SNHG11 levels are associated with advanced stage or metastasis in gastric cancer patients, while H19 levels positively correlate with tumor grades [46, 83]. Patients with increased levels of SNHG11, H19, and LINC01226 have shorter overall survival (OS) [46]. Functionally, SNHG11, lncRNA HOXC-AS1, ZEB2-AS1, and LINC01226 promote cell proliferation and migration in gastric cancer [46, 81, 84, 85]. SNHG11 also enhances stemness in gastric cancer cell lines [46]. Knockdown of ZFAS1 increases sensitivity to cisplatin or paclitaxel, while [82] silencing H19 significantly reduces metastatic nodules in the lung and liver [83]. Downregulation of SNHG11 results in slower tumor growth and reduced levels of the stemness marker, CD133, in gastric cancer [46]. Mechanistically, SNHG11 and HOXC-AS1 enhance cell invasion by interacting with CUL4A and eIF4AIII, respectively, to activate the Wnt/β-catenin pathway [46]. SNHG11 also regulates autophagy independently of this mechanism [46]. HOXC-AS1 can enhance proliferation, promote EMT, and inhibit apoptosis through its interaction with eIF4AIII in the Wnt/β-catenin signaling pathway [85]. Knockdown of ZFAS1 suppresses cell motility and chemotherapeutic tolerance although these effects can be reversed by β-catenin overexpression [82]. H19 facilitates β-catenin translocation into the nucleus, activating the Wnt/β-catenin pathway and promoting cell motility and metastatic potential [86]. LINC01226 disrupts the STIP1-HSP90 complex, enhancing Wnt/β-catenin signaling and metastatic potential.

Role of Wnt pathway-associated lncRNAs in suppressing gastric cancer

LINC01133 expression is reduced in ESCC tissues and cell lines [87, 88], and its expression negatively correlates with tumor size, distant metastasis, and peritoneum dissemination in gastric cancer patients [87]. Patients with low LINC01133 expression have a significantly poorer prognosis [87]. Similarly, a decrease in serum GASL1 levels is observed, which negatively correlates with overall survival (OS) in gastric cancer patients [88]. Serum GASL1 levels may serve as a prognostic biomarker for gastric cancer. Functionally, LINC01133 and GASL1 inhibit cell proliferation [87, 88]. The LINC01133/miR-106a-3p/APC axis governs metastasis in gastric cancer cells in a Wnt-dependent manner [87]. The inhibitory effect of GASL1 overexpression on cell growth is diminished by treatment with a Wnt agonist, suggesting [88] that the Wnt agonist interacts with pathways downstream of GASL1. Further investigation is needed to elucidate these mechanisms and their potential therapeutic implications.

Liver cancer

Role of Wnt pathway-associated lncRNAs in promoting liver cancer

In liver cancer, the expression of lncRNAs, including PRR34-AS1, SNHG5, lncRNA-DAW, FOXD2-AS1, CTB-193M12.5, lncRNA-CR594175, and lncRNA-MUF is significantly upregulated. Among these, SNHG5 is notably correlated with clinical features such as tumor size, histologic grade, and TNM stage in HCC [89]. Additionally, lncRNA-CR594175 expression was higher in metastatic HCC than in primary HCC [90]. Elevated levels of SNHG5, FOXD2-AS1, and CTB-193M12.5 are linked to poorer prognosis [89, 91, 92]. Functionally, PRR34-AS1, SNHG5, lncRNA-DAW, FOXD2-AS1, CTB-193M12.5, and lncRNA-CR594175 enhance the cell proliferation in liver cancer [8, 90–94]. lncRNA-MUF promotes EMT, contributing to HCC progression, although its role in cell proliferation remains to be explored [95]. SNHG5 also augments the cancer stem cell (CSC)–like properties of HCC cells, indicated by a reduced expression of CSC markers (CD44, CD133, and ALDH1) and transcription factors (OCT4, SOX2, and NANOG) upon SNHG5 knockdown [8]. Mechanistically SNHG5 promotes HCC cell proliferation and CSC–like properties by modulating UPF1 and the Wnt/β-catenin pathway (Fig. 3). Treatment with XAV-939, an inhibitor of the Wnt/β-catenin pathway, impairs spheroid formation and reduces the number of spheroids in liver CSCs, suggesting its potential as a therapeutic agent for targeting CSCs self-renewal [8]. Furthermore, lncRNA-DAW enhances invasion by activating Wnt2 through EZH2 degradation [94]. FOXD2-AS1, upregulated by EGR1, drives HCC progression by silencing DKK1 and activating Wnt/β-catenin signaling [91]. CTB-193M12.5 promotes WNT10B transcription via epigenetic activation, further enhancing Wnt/β-catenin signaling [92]. Suppression of lncRNA-CR594175 inhibits HCC cell growth by restoring hsa-miR-142-3p’s regulation of CTNNB1 [90]. Additionally, lncRNA-MUF promotes metastasis by binding to Annexin A2 (ANXA2) and activating the Wnt/β-catenin signaling pathway [95].Fig. 3 Mechanisms of the lncRNA/Wnt axis in liver cancer. lncRNA PRR34-AS1 promotes the development of hepatocellular carcinoma (HCC). LncRNA PRR34-AS1 plays a pivotal role in hepatocellular carcinoma (HCC) development by modulating the miR-296-5p/E2F2/SOX12/Wnt/β-catenin axis. It achieves this by absorbing miR-296-5p and upregulating the expression of E2F2 and SOX12, both of which are critical for HCC progression. Additionally, SNHG5 regulates liver cancer progression by modulating UPF1 and the Wnt/β-catenin pathway. In liver cancer, lncRNA-DAW facilitates EZH2 degradation, leading to Wnt/β-catenin pathway activation. Furthermore, the upregulated expression of lncRNA FOXD2-AS1, induced by EGR1, drives HCC progression by silencing DKK1 and activating the Wnt/β-catenin signaling pathway. CTB-193M12.5 promotes WNT10B expression to facilitate HCC progression. Lastly, lncRNA-CR594175 enhances the Wnt pathway, promoting HCC cell growth by downregulating miR-142-3p. Additionally, lncRNA-MUF promotes HCC progression by binding to Annexin A2 (ANXA2) and activating the Wnt/β-catenin signaling pathway

Role of Wnt pathway-associated lncRNAs in suppressing liver cancer

Conversely, lncRNAs KB-68A7.1 and lncRNA-NEF are significantly downregulated in liver cancer [96, 97]. Patients with lower lncRNA-NEF expression exhibit larger tumors, more aggressive clinical characteristics, and poorer survival outcomes. [96]. Overexpression of lncRNA-NEF inhibits EMT and cell migration, while in vivo studies show that lncRNA-NEF and KB-68A7.1 suppress HCC tumor growth and metastasis [96, 97]. Mechanistically, KB-68A7.1 exerts its tumor-suppressive effects by sequestering NSD1 in the cytoplasm, reducing WNT10B transcription and repressing Wnt/β-catenin signaling, and ultimately inhibiting tumor progression [96]. The reduced cellular proliferation and motility from KB-68A7.1 overexpression was reversed by ectopic WNT10B expression, while the Wnt/β-catenin signaling inhibitor ICG-001 counter the proliferation effects of KB-68A7.1 overexpression [96], highlighting its therapeutic potential. Additionally, lncRNA-NEF interacts with β-catenin, enhancing the association between GSK3β and β-catenin [97], thereby elucidating its role in HCC metastasis through the Wnt/β-catenin pathway.

Colorectal cancer

Role of Wnt pathway-associated lncRNAs in promoting colorectal cancer

Several Wnt pathway-related lncRNAs including STEAP3-AS1, MIR100HG, LEF1-AS1, PART1, LINC01606, H19, SLCO4A1-AS1, AC010789.1, CRNDE, and HOTAIR, are significantly upregulated in colorectal cancer [20, 98–106]. Cetuximab, a commonly used targeted therapy for colorectal cancer, often leads to drug resistance during treatment. Elevated levels of LINC01606 and AC010789 are positively associated with lymph node metastasis, and LINC01606 is also linked to distant metastasis [101, 104]. Patients with increased expression of STEAP3-AS1, LINC01606, H19, SLCO4A1-AS1, AC010789.1, CRNDE, and HOTAIR have a worse prognosis [98, 101–106]. Functionally, the overexpression of STEAP3-AS1, LEF1-AS1, PART1, LINC01606, H19, SLCO4A1-AS1, and AC010789.1 promotes cell proliferation, migration, and invasion in colorectal cancer cell lines [20, 100–104, 107]. Conversely, the downregulation of MIR100HG, CRNDE, and HOTAIR significantly lowers cetuximab resistance in colorectal cancer cells, in vitro and in vivo [99, 108]. Suppression of LEF1-AS1 inhibits tumor growth, as well as liver and lung metastasis in vivo [100]. Mechanistically, STEAP3-AS1 drives colorectal cancer progression by regulating the STEAP3/GSK3β/Wnt/β-catenin axis [98]. Downregulation of STEAP3-AS1 triggers cytoplasmic sequestration of β-catenin, which can be reversed by reintroducing STEAP3, thereby promoting invasion and metastasis [109]. MIR100HG interacts with hnRNPA2B1 to stabilize TCF7L2 mRNA, a crucial coactivator in Wnt/β-catenin signaling [108]. LEF1-AS1 promotes cell motility by increasing FUT8 expression and α1,6-fucosylation levels via the Wnt/β-catenin pathway [100]. PART1 acts as a ceRNA, sequestering miR-150-5p and miR-520 h, leading to upregulated expression of CTNNB1 and subsequent activation of the Wnt/β-catenin pathway, thereby promoting cell migration and invasion [20]. The H19/miR-29-3b/PGRN/Wnt signaling pathway promotes the onset of EMT in colorectal cancer [102]. SLCO4A1-AS1 interferes with the interaction between β-catenin and GSKβ, reducing β-catenin phosphorylation and enhancing stability in colorectal cancer cells [103]. CRNDE facilitates colorectal cancer cell proliferation and chemoresistance through the miR-181a-5p/Wnt/β-catenin axis [105].

Pancreatic cancer

Role of Wnt pathway-associated lncRNAs in promoting pancreatic cancer

In pancreatic cancer tissues and cell lines, the expression of PVT1, SH3BP5-AS1, LINC01614, OIP5-AS1, and FAM83H-AS1 is significantly upregulated (Fig. 1) [110–114]. Elevated levels of SH3BP5-AS1, LINC01614, and FAM83H-AS1 correlate with a worse prognosis [111, 112, 114]. Gemcitabine (GEM), a commonly used first-line chemotherapeutic drug for pancreatic cancer, faces challenges such as drug resistance and side effects. PVT1 has been shown to promote GEM resistance in pancreatic cancer cells, confirmed through in vivo studies [110]. Additionally, SH3BP5-AS1, LINC01614, OIP5-AS1, and FAM83H-AS1 enhance cell proliferation, migration, and invasion in pancreatic cancer cell lines [111–114]. Inhibition of LINC01614 significantly suppresses tumor growth in pancreatic cancer [112].

Mechanistically, PVT1 enhances gemcitabine resistance by activating the Wnt/β-catenin and autophagy pathways in pancreatic cancer, mediated via the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes [110]. SH3BP5-AS1 enhances CTBP1 expression, promoting gemcitabine resistance by activating the Wnt signaling pathway [111]. LINC01614 interacts with GSK-3β, disrupting its interaction with AXIN1, thereby upregulating β-catenin levels, which promotes cell migration and invasion [112]. OIP5-AS1 silences miR-320b, upregulating FOXM1expression, which activates the Wnt/β-catenin pathway and promotes invasive behavior [113]. FAM83H-AS1, by promoting FAM83H expression, reduces β-catenin ubiquitination, activating the Wnt/β-catenin pathway and facilitating pancreatic cancer progression [114].

Role of Wnt pathway-associated lncRNAs in suppressing pancreatic cancer

LINC01197 expression is significantly downregulated in pancreatic cancer tissues [115]. This reduced expression is strongly correlated with unfavorable disease-free prognosis and OS in pancreatic cancer patients [115]. Functionally, LINC01197 significantly inhibits the growth of pancreatic cancer in vitro and in vivo [115]. By interacting with LINC01197, FOXO1 disrupts the interaction between β-catenin and TCF4, inhibiting cell proliferation in pancreatic cancer [115].

Wnt pathway-associated lncRNAs as a biomarker

Advancements in technology have shed light on the role of the lncRNA/Wnt axis in tumorigenesis and disease development. lncRNAs hold potential as targets for diagnosing, prognosing, and treating digestive system tumors, with the lncRNA/Wnt axis showing great promise for clinical applications.

Wnt pathway-associated lncRNAs as a diagnostic biomarker

The expression of Wnt pathway-associated lncRNAs is significantly dysregulated in esophageal, gastric, liver, colorectal, and pancreatic cancers, making them potential biomarkers for diagnosing these digestive system tumors. Certain Wnt pathway-associated lncRNAs have shown promising diagnostic value in differentiating between digestive system tumor tissues and normal tissues. For instance, EWSAT1 expression levels significantly distinguish between ESCC patients and healthy controls, with an area under the curve (AUC) of 0.7174, indicating its diagnostic potential [116]. Similarly, LINC01606 expression can accurately discriminate patients with colorectal cancer from healthy controls, with an area under the receiver operating characteristic (ROC) of 0.725 [101]. SLCO4A1-AS1 has an AUC of 0.924, highlighting its excellent predictive value for colorectal cancer [103]. ROC analysis suggests thatSH3BP5-AS1 is a valuable prognostic biomarker for pancreatic cancer (AUC = 0.816) [111]. Although the differential expression of Wnt pathway-associated lncRNAs at the tissue level may present some challenges for clinical application, certain lncRNAs also show distinct levels in plasma. For example, in patients with ESCC, plasma level of the Wnt pathway-associated lncRNA, NEF, was significantly lower compared to healthy controls [19]. ROC analysis demonstrated that plasma NEF has significant diagnostic value for ESCC, with an AUC of 0.9042. Similarly, plasma levels of lncRNA GASL1 were significantly decreased in patients with gastric cancer compared to healthy controls, with an AUC of 0.8945 for differentiating gastric cancer patients from normal subjects [19, 88]. These findings suggest that plasma levels of Wnt pathway-associated lncRNAs hold potential clinical significance in diagnosing ESCC and gastric cancer. Further research is needed to validate these findings and explore the underlying mechanisms of these lncRNAs in tumor development.

Wnt pathway-associated lncRNAs as a prognostic biomarker

Identifying effective prognostic biomarkers during cancer treatment is crucial for predicting patient survival, guiding treatment selection, and monitoring treatment efficacy [117]. However, accurately predicting the prognosis of patients with digestive system tumors is challenging due to tumor heterogeneity, molecular variability, and various interfering factors. Multiple studies have highlighted the potential of Wnt pathway-associated lncRNAs as prognostic biomarkers in digestive system tumors. The expression of these lncRNAs is significantly associated with various prognostic characteristics in patients. Lower expression levels of certain lncRNAs are linked to a higher likelihood of disease recurrence or progression, leading to poorer disease-free survival. For example, HERES expression correlates with lower rates of stage-free survival in esophageal cancer [74]. Both univariate and multivariate analyses have shown that decreased expression of MEG3 independently predicts shorter disease-free survival and OS [18]. Similarly, downregulated GASL1 expression is associated with decreased postoperative survival time for gastric cancer [88]. Conversely, increased levels of LINC01226 are positively correlated with shorter progression-free survival or OS in gastric cancer patients [84]. These findings underscore the potential of Wnt pathway-related lncRNAs as valuable biomarkers for predicting patient outcomes in digestive system tumors. Exploring the intricate relationship between lncRNA expression and prognostic features may provide novel insights and identify potential therapeutic targets to enhance patient outcomes in digestive system cancers.

However, several challenges and limitations must be addressed before Wnt pathway-related lncRNAs can be effectively used in clinical practice. Tissue specificity, sensitivity, and reproducibility are major concerns. Differential expression of these lncRNAs at the tissue level complicates consistent and reliable sample collection across patient populations. Tumor heterogeneity and molecular variability further affect the reliability of lncRNAs as biomarkers. Standardized methodologies for detecting and quantifying Wnt pathway-related lncRNAs are crucial to overcoming these issues. While Wnt pathway-associated lncRNAs offer promising diagnostic and prognostic potential, further research and standardization are essential for their successful clinical application.

Targeting lncRNA/Wnt axis for therapy

Carcinogenesis involves the gradual accumulation of genetic and epigenetic alterations [118–120]. Studying tumor molecular mechanisms, which has been the research focus in recent years, enhances our understanding of cancer pathogenesis and informs targeted therapies. These alterations affect genes related to cell growth, DNA repair, and cell signaling pathways [121, 122]. For example, oncogene mutations or tumor suppressor gene dysregulation can lead to uncontrolled cell proliferation and tumor formation [123]. Targeted therapies aim to selectively modulate specific molecules or pathways involved in tumor growth and survival. Biomarker discovery plays a crucial role in treatment decisions. Some lncRNAs inhibit Wnt pathway activation, reducing proliferation and invasiveness, while others activate it, promoting tumor growth and metastasis. Wnt pathway-related lncRNAs provide new targets for tumor therapy and insights into cancer treatment. Researchers and clinical doctors can identify therapeutic targets and develop personalized strategies by understanding alterations in these lncRNAs. Discussing current strategies, such as using antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to knock down oncogenic lncRNAs, would be beneficial. Small molecule inhibitors targeting the Wnt signaling pathway, such as ICG-001 and PRI-724 disrupt the interaction between β-catenin and TCF/LEF transcription factors [8]. This inhibition reduces Wnt target gene expression and has shown efficacy in preclinical models. Ongoing clinical trials evaluate the safety and efficacy of these inhibitors in patients with various cancers, including digestive system tumors. Another promising approach involves CRISPR/Cas9 technology to edit lncRNA genes, potentially correcting mutations or dysregulations contributing to tumorigenesis. This precise genome-editing technique allows the investigation of specific lncRNA functions and the development of targeted cancer therapies.

Bridging preclinical and clinical research on the lncRNA/Wnt axis in digestive system cancers

Research on the interaction between the Wnt/β-catenin signaling pathway and lncRNAs in digestive system cancers primarily relies on cell and animal models. However, clinical validation is lacking. To demonstrate the translational relevance of these findings, more comprehensive clinical investigations are needed. Research using cell and animal models has revealed the crucial role of the Wnt/β-catenin signaling pathway in cancer progression. However, clinical validation in patient samples is necessary. For example, studies indicate that overactivation of the Wnt/β-catenin pathway in colorectal cancer, gastric cancer, and HCC is closely linked to cancer stem cell proliferation, EMT, chemoresistance, and metastasis [46, 83, 91, 103]. The lack of direct validation in human patients leaves the clinical applicability of these findings uncertain. To enhance the translational value, future research should prioritize conducting more studies with clinical samples to validate the interactions between the Wnt/β-catenin signaling pathway and lncRNAs in cancer progression. Additionally, initiating clinical trials to assess the efficacy and safety of therapies targeting the Wnt/β-catenin pathway and lncRNAs is essential. Undertaking multi-center studies to collect larger patient datasets will verify the generality and clinical relevance of these mechanisms across diverse populations.

Conclusions and future perspectives

The Wnt pathway plays a crucial in cell growth, differentiation, and development, by regulating the biological functions through protein interactions. Dysregulation of the Wnt pathway is linked to various digestive system cancers. LncRNAs, which are RNA molecules longer than 200 nucleotides can regulate gene expression through different pathways. In esophageal, gastric, liver, colorectal, and pancreatic cancers, the expression of Wnt pathway-associated lncRNAs is significantly altered, making them potential biomarkers for tumor diagnosis. Some of these lncRNAs have shown promise in distinguishing tumor tissues from normal tissues. Understanding Wnt pathway-related lncRNAs can help identify treatment targets and develop personalized cancer therapies. Specifically, Wnt pathway-related lncRNAs can affect the activity of the Wnt pathway through various mechanisms, thus regulating tumor growth, metastasis, and invasion. Therefore, Wnt pathway-related lncRNAs represent potential targets for cancer treatment. Wnt pathway inhibitors also offer therapeutic options for digestive system tumors. Understanding the changes in Wnt pathway-associated lncRNAs can help researchers and clinicians identify treatment targets and develop personalized cancer treatment strategies.

Author contributions

Penghui Li designed the work, Xiao Ma, and Di Huang wrote this manuscript, and made figures. All authors read and approved the final manuscript.

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors agree to publish.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Yuan S Mason AM Titova OE Vithayathil M Kar S Chen J Li X Burgess S Larsson SC Morning chronotype and digestive tract cancers: Mendelian randomization study Int J Cancer 2023 152 697 704 10.1002/ijc.34284 36093575
Yuan S, Mason AM, Titova OE, Vithayathil M, Kar S, Chen J, Li X, Burgess S, Larsson SC. Morning chronotype and digestive tract cancers: Mendelian randomization study. Int J Cancer. 2023;152:697–704.36093575 10.1002/ijc.34284
2. Kumar S Prajapati KS Singh AK Kushwaha PP Shuaib M Gupta S Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer Cancer Lett 2021 504 15 22 10.1016/j.canlet.2020.11.039 33556545
Kumar S, Prajapati KS, Singh AK, Kushwaha PP, Shuaib M, Gupta S. Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer. Cancer Lett. 2021;504:15–22.33556545 10.1016/j.canlet.2020.11.039
3. Eptaminitaki GC Stellas D Bonavida B Baritaki S Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: from prediction to druggability Drug Resist Updat 2022 65 100866 10.1016/j.drup.2022.100866 36198236
Eptaminitaki GC, Stellas D, Bonavida B, Baritaki S. Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: from prediction to druggability. Drug Resist Updat. 2022;65: 100866.36198236 10.1016/j.drup.2022.100866
4. Zhang F Li J Xiao H Zou Y Liu Y Huang W AFAP1-AS1: a novel oncogenic long non-coding RNA in human cancers Cell Prolif 2018 51 e12397 10.1111/cpr.12397 29057544
Zhang F, Li J, Xiao H, Zou Y, Liu Y, Huang W. AFAP1-AS1: a novel oncogenic long non-coding RNA in human cancers. Cell Prolif. 2018;51: e12397.29057544 10.1111/cpr.12397
5. Song W Zhang RJ Zou SB Long noncoding RNA MALAT1 as a potential novel biomarker in digestive system cancers: a meta-analysis Minerva Med 2016 107 245 250 27348442
Song W, Zhang RJ, Zou SB. Long noncoding RNA MALAT1 as a potential novel biomarker in digestive system cancers: a meta-analysis. Minerva Med. 2016;107:245–50.27348442
6. Qian X Zhao J Yeung PY Zhang QC Kwok CK Revealing lncRNA structures and interactions by sequencing-based approaches Trends Biochem Sci 2019 44 33 52 10.1016/j.tibs.2018.09.012 30459069
Qian X, Zhao J, Yeung PY, Zhang QC, Kwok CK. Revealing lncRNA structures and interactions by sequencing-based approaches. Trends Biochem Sci. 2019;44:33–52.30459069 10.1016/j.tibs.2018.09.012
7. Hashemi M Moosavi MS Abed HM Dehghani M Aalipour M Heydari EA Behroozaghdam M Entezari M Salimimoghadam S Gunduz ES Long non-coding RNA (lncRNA) H19 in human cancer: from proliferation and metastasis to therapy Pharmacol Res 2022 184 106418 10.1016/j.phrs.2022.106418 36038043
Hashemi M, Moosavi MS, Abed HM, Dehghani M, Aalipour M, Heydari EA, Behroozaghdam M, Entezari M, Salimimoghadam S, Gunduz ES, et al. Long non-coding RNA (lncRNA) H19 in human cancer: from proliferation and metastasis to therapy. Pharmacol Res. 2022;184: 106418.36038043 10.1016/j.phrs.2022.106418
8. Li Y Hu J Guo D Ma W Zhang X Zhang Z Lu G He S LncRNA SNHG5 promotes the proliferation and cancer stem cell-like properties of HCC by regulating UPF1 and Wnt-signaling pathway Cancer Gene Ther 2022 29 1373 1383 10.1038/s41417-022-00456-3 35338348
Li Y, Hu J, Guo D, Ma W, Zhang X, Zhang Z, Lu G, He S. LncRNA SNHG5 promotes the proliferation and cancer stem cell-like properties of HCC by regulating UPF1 and Wnt-signaling pathway. Cancer Gene Ther. 2022;29:1373–83.35338348 10.1038/s41417-022-00456-3
9. He XY Fan X Qu L Wang X Jiang L Sang LJ Shi CY Lin S Yang JC Yang ZZ LncRNA modulates Hippo-YAP signaling to reprogram iron metabolism Nat Commun 2023 14 2253 10.1038/s41467-023-37871-5 37080959
He XY, Fan X, Qu L, Wang X, Jiang L, Sang LJ, Shi CY, Lin S, Yang JC, Yang ZZ, et al. LncRNA modulates Hippo-YAP signaling to reprogram iron metabolism. Nat Commun. 2023;14:2253.37080959 10.1038/s41467-023-37871-5
10. Mallela VR Rajtmajerová M Trailin A Liška V Hemminki K Ambrozkiewicz F miRNA and lncRNA as potential tissue biomarkers in hepatocellular carcinoma Noncoding RNA Res 2024 9 24 32 10.1016/j.ncrna.2023.10.010 38075204
Mallela VR, Rajtmajerová M, Trailin A, Liška V, Hemminki K, Ambrozkiewicz F. miRNA and lncRNA as potential tissue biomarkers in hepatocellular carcinoma. Noncoding RNA Res. 2024;9:24–32.38075204 10.1016/j.ncrna.2023.10.010
11. Hu L Xie K Zheng C Qiu B Jiang Z Luo C Diao Y Luo J Yao X Shen Y Exosomal MALAT1 promotes the proliferation of esophageal squamous cell carcinoma through glyoxalase 1-dependent methylglyoxal removal Noncoding RNA Res 2024 9 330 340 10.1016/j.ncrna.2024.01.003 38505306
Hu L, Xie K, Zheng C, Qiu B, Jiang Z, Luo C, Diao Y, Luo J, Yao X, Shen Y. Exosomal MALAT1 promotes the proliferation of esophageal squamous cell carcinoma through glyoxalase 1-dependent methylglyoxal removal. Noncoding RNA Res. 2024;9:330–40.38505306 10.1016/j.ncrna.2024.01.003
12. Tu C Yang K Wan L He J Qi L Wang W Lu Q Li Z The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression Cell Prolif 2020 53 e12887 10.1111/cpr.12887 32779318
Tu C, Yang K, Wan L, He J, Qi L, Wang W, Lu Q, Li Z. The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression. Cell Prolif. 2020;53: e12887.32779318 10.1111/cpr.12887
13. Ebrahimi N Parkhideh S Samizade S Esfahani AN Samsami S Yazdani E Adelian S Chaleshtori SR Shah-Amiri K Ahmadi A Crosstalk between lncRNAs in the apoptotic pathway and therapeutic targets in cancer Cytokine Growth Factor Rev 2022 65 61 74 10.1016/j.cytogfr.2022.04.003 35597701
Ebrahimi N, Parkhideh S, Samizade S, Esfahani AN, Samsami S, Yazdani E, Adelian S, Chaleshtori SR, Shah-Amiri K, Ahmadi A, et al. Crosstalk between lncRNAs in the apoptotic pathway and therapeutic targets in cancer. Cytokine Growth Factor Rev. 2022;65:61–74.35597701 10.1016/j.cytogfr.2022.04.003
14. Hashemi M Hasani S Hajimazdarany S Mirmazloomi SR Makvandy S Zabihi A Goldoost Y Gholinia N Kakavand A Tavakolpournegari A Non-coding RNAs targeting notch signaling pathway in cancer: from proliferation to cancer therapy resistance Int J Biol Macromol 2022 222 1151 1167 10.1016/j.ijbiomac.2022.09.203 36191781
Hashemi M, Hasani S, Hajimazdarany S, Mirmazloomi SR, Makvandy S, Zabihi A, Goldoost Y, Gholinia N, Kakavand A, Tavakolpournegari A, et al. Non-coding RNAs targeting notch signaling pathway in cancer: from proliferation to cancer therapy resistance. Int J Biol Macromol. 2022;222:1151–67.36191781 10.1016/j.ijbiomac.2022.09.203
15. Rim EY Clevers H Nusse R The Wnt pathway: from signaling mechanisms to synthetic modulators Annu Rev Biochem 2022 91 571 598 10.1146/annurev-biochem-040320-103615 35303793
Rim EY, Clevers H, Nusse R. The Wnt pathway: from signaling mechanisms to synthetic modulators. Annu Rev Biochem. 2022;91:571–98.35303793 10.1146/annurev-biochem-040320-103615
16. Nusse R Clevers H Wnt/β-catenin signaling, disease, and emerging therapeutic modalities Cell 2017 169 985 999 10.1016/j.cell.2017.05.016 28575679
Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985–99.28575679 10.1016/j.cell.2017.05.016
17. Ren Y Guo T Xu J Liu Y Huang J The novel target of esophageal squamous cell carcinoma: lncRNA GASL1 regulates cell migration, invasion and cell cycle stagnation by inactivating the Wnt3a/β-catenin signaling Pathol Res Pract 2021 217 153289 10.1016/j.prp.2020.153289 33248356
Ren Y, Guo T, Xu J, Liu Y, Huang J. The novel target of esophageal squamous cell carcinoma: lncRNA GASL1 regulates cell migration, invasion and cell cycle stagnation by inactivating the Wnt3a/β-catenin signaling. Pathol Res Pract. 2021;217: 153289.33248356 10.1016/j.prp.2020.153289
18. Ma J Li TF Han XW Yuan HF Downregulated MEG3 contributes to tumour progression and poor prognosis in oesophagal squamous cell carcinoma by interacting with miR-4261, downregulating DKK2 and activating the Wnt/β-catenin signalling Artif Cells Nanomed Biotechnol 2019 47 1513 1523 10.1080/21691401.2019.1602538 30990378
Ma J, Li TF, Han XW, Yuan HF. Downregulated MEG3 contributes to tumour progression and poor prognosis in oesophagal squamous cell carcinoma by interacting with miR-4261, downregulating DKK2 and activating the Wnt/β-catenin signalling. Artif Cells Nanomed Biotechnol. 2019;47:1513–23.30990378 10.1080/21691401.2019.1602538
19. Zhang J Hu SL Qiao CH Ye JF Li M Ma HM Wang JH Xin SY Yuan ZL LncRNA-NEF inhibits proliferation, migration and invasion of esophageal squamous-cell carcinoma cells by inactivating wnt/β-catenin pathway Eur Rev Med Pharmacol Sci 2018 22 6824 6831 30402846
Zhang J, Hu SL, Qiao CH, Ye JF, Li M, Ma HM, Wang JH, Xin SY, Yuan ZL. LncRNA-NEF inhibits proliferation, migration and invasion of esophageal squamous-cell carcinoma cells by inactivating wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci. 2018;22:6824–31.30402846
20. Zhou T Wu L Ma N Tang F Zong Z Chen S LncRNA PART1 regulates colorectal cancer via targeting miR-150-5p/miR-520h/CTNNB1 and activating Wnt/β-catenin pathway Int J Biochem Cell Biol 2020 118 105637 10.1016/j.biocel.2019.105637 31669140
Zhou T, Wu L, Ma N, Tang F, Zong Z, Chen S. LncRNA PART1 regulates colorectal cancer via targeting miR-150-5p/miR-520h/CTNNB1 and activating Wnt/β-catenin pathway. Int J Biochem Cell Biol. 2020;118: 105637.31669140 10.1016/j.biocel.2019.105637
21. Swarup S Verheyen EM Wnt/Wingless signaling in Drosophila Cold Spring Harb Perspect Biol 2012 4 a007930 10.1101/cshperspect.a007930 22535229
Swarup S, Verheyen EM. Wnt/Wingless signaling in Drosophila. Cold Spring Harb Perspect Biol. 2012;4: a007930.22535229 10.1101/cshperspect.a007930
22. Bejsovec A Flying at the head of the pack: Wnt biology in Drosophila Oncogene 2006 25 7442 7449 10.1038/sj.onc.1210051 17143288
Bejsovec A. Flying at the head of the pack: Wnt biology in Drosophila. Oncogene. 2006;25:7442–9.17143288 10.1038/sj.onc.1210051
23. Ueno K Hirata H Hinoda Y Dahiya R Frizzled homolog proteins, microRNAs and Wnt signaling in cancer Int J Cancer 2013 132 1731 1740 10.1002/ijc.27746 22833265
Ueno K, Hirata H, Hinoda Y, Dahiya R. Frizzled homolog proteins, microRNAs and Wnt signaling in cancer. Int J Cancer. 2013;132:1731–40.22833265 10.1002/ijc.27746
24. DeBruine ZJ Xu HE Melcher K Assembly and architecture of the Wnt/β-catenin signalosome at the membrane Br J Pharmacol 2017 174 4564 4574 10.1111/bph.14048 28941231
DeBruine ZJ, Xu HE, Melcher K. Assembly and architecture of the Wnt/β-catenin signalosome at the membrane. Br J Pharmacol. 2017;174:4564–74.28941231 10.1111/bph.14048
25. Kikuchi A Yamamoto H Kishida S Multiplicity of the interactions of Wnt proteins and their receptors Cell Signal 2007 19 659 671 10.1016/j.cellsig.2006.11.001 17188462
Kikuchi A, Yamamoto H, Kishida S. Multiplicity of the interactions of Wnt proteins and their receptors. Cell Signal. 2007;19:659–71.17188462 10.1016/j.cellsig.2006.11.001
26. Nusse R Wnt signaling and stem cell control Cell Res 2008 18 523 527 10.1038/cr.2008.47 18392048
Nusse R. Wnt signaling and stem cell control. Cell Res. 2008;18:523–7.18392048 10.1038/cr.2008.47
27. Johnson ML Rajamannan N Diseases of Wnt signaling Rev Endocr Metab Disord 2006 7 41 49 10.1007/s11154-006-9003-3 16944325
Johnson ML, Rajamannan N. Diseases of Wnt signaling. Rev Endocr Metab Disord. 2006;7:41–9.16944325 10.1007/s11154-006-9003-3
28. VanderVorst K Dreyer CA Konopelski SE Lee H Ho HH Carraway KL 3rd Wnt/pcp signaling contribution to carcinoma collective cell migration and metastasis Cancer Res 2019 79 1719 1729 10.1158/0008-5472.CAN-18-2757 30952630
VanderVorst K, Dreyer CA, Konopelski SE, Lee H, Ho HH, Carraway KL. 3rd Wnt/pcp signaling contribution to carcinoma collective cell migration and metastasis. Cancer Res. 2019;79:1719–29.30952630 10.1158/0008-5472.CAN-18-2757
29. Liang J Fu Y Cruciat CM Jia S Wang Y Tong Z Tao Q Ingelfinger D Boutros M Meng A Transmembrane protein 198 promotes LRP6 phosphorylation and Wnt signaling activation Mol Cell Biol 2011 31 2577 2590 10.1128/MCB.05103-11 21536646
Liang J, Fu Y, Cruciat CM, Jia S, Wang Y, Tong Z, Tao Q, Ingelfinger D, Boutros M, Meng A, et al. Transmembrane protein 198 promotes LRP6 phosphorylation and Wnt signaling activation. Mol Cell Biol. 2011;31:2577–90.21536646 10.1128/MCB.05103-11
30. Zeng X Huang H Tamai K Zhang X Harada Y Yokota C Almeida K Wang J Doble B Woodgett J Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions Development 2008 135 367 375 10.1242/dev.013540 18077588
Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, Almeida K, Wang J, Doble B, Woodgett J, et al. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development. 2008;135:367–75.18077588 10.1242/dev.013540
31. Albrecht LV Tejeda-Muñoz N De Robertis EM Cell biology of canonical Wnt signaling Annu Rev Cell Dev Biol 2021 37 369 389 10.1146/annurev-cellbio-120319-023657 34196570
Albrecht LV, Tejeda-Muñoz N, De Robertis EM. Cell biology of canonical Wnt signaling. Annu Rev Cell Dev Biol. 2021;37:369–89.34196570 10.1146/annurev-cellbio-120319-023657
32. Khan S Kwak YT Peng L Hu S Cantarel BL Lewis CM Gao Y Mani RS Kanneganti TD Zaki H NLRP12 downregulates the Wnt/β-catenin pathway via interaction with STK38 to suppress colorectal cancer J Clin Invest 2023 133 e166295 10.1172/JCI166295 37581937
Khan S, Kwak YT, Peng L, Hu S, Cantarel BL, Lewis CM, Gao Y, Mani RS, Kanneganti TD, Zaki H. NLRP12 downregulates the Wnt/β-catenin pathway via interaction with STK38 to suppress colorectal cancer. J Clin Invest. 2023;133: e166295.37581937 10.1172/JCI166295
33. Lin J Song T Li C Mao W GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer Biochim Biophys Acta Mol Cell Res 2020 1867 118659 10.1016/j.bbamcr.2020.118659 31978503
Lin J, Song T, Li C, Mao W. GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. Biochim Biophys Acta Mol Cell Res. 2020;1867: 118659.31978503 10.1016/j.bbamcr.2020.118659
34. Doumpas N Lampart F Robinson MD Lentini A Nestor CE Cantù C Basler K TCF/LEF dependent and independent transcriptional regulation of Wnt/β-catenin target genes Embo J 2019 38 e98873 10.15252/embj.201798873 30425074
Doumpas N, Lampart F, Robinson MD, Lentini A, Nestor CE, Cantù C, Basler K. TCF/LEF dependent and independent transcriptional regulation of Wnt/β-catenin target genes. Embo J. 2019;38: e98873.30425074 10.15252/embj.201798873
35. Danek P Kardosova M Janeckova L Karkoulia E Vanickova K Fabisik M Lozano-Asencio C Benoukraf T Tirado-Magallanes R Zhou Q β-Catenin-TCF/LEF signaling promotes steady-state and emergency granulopoiesis via G-CSF receptor upregulation Blood 2020 136 2574 2587 10.1182/blood.2019004664 32822472
Danek P, Kardosova M, Janeckova L, Karkoulia E, Vanickova K, Fabisik M, Lozano-Asencio C, Benoukraf T, Tirado-Magallanes R, Zhou Q, et al. β-Catenin-TCF/LEF signaling promotes steady-state and emergency granulopoiesis via G-CSF receptor upregulation. Blood. 2020;136:2574–87.32822472 10.1182/blood.2019004664
36. Clevers H Nusse R Wnt/β-catenin signaling and disease Cell 2012 149 1192 1205 10.1016/j.cell.2012.05.012 22682243
Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149:1192–205.22682243 10.1016/j.cell.2012.05.012
37. Yu F Yu C Li F Zuo Y Wang Y Yao L Wu C Wang C Ye L Wnt/β-catenin signaling in cancers and targeted therapies Signal Transduct Target Ther 2021 6 307 10.1038/s41392-021-00701-5 34456337
Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, Wu C, Wang C, Ye L. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6:307.34456337 10.1038/s41392-021-00701-5
38. Zhang Y Zhang C Peng C Jia J Unraveling the crosstalk: circRNAs and the wnt signaling pathway in cancers of the digestive system Noncoding RNA Res 2024 9 853 864 10.1016/j.ncrna.2024.03.004 38586314
Zhang Y, Zhang C, Peng C, Jia J. Unraveling the crosstalk: circRNAs and the wnt signaling pathway in cancers of the digestive system. Noncoding RNA Res. 2024;9:853–64.38586314 10.1016/j.ncrna.2024.03.004
39. MacDonald BT Tamai K He X Wnt/beta-catenin signaling: components, mechanisms, and diseases Dev Cell 2009 17 9 26 10.1016/j.devcel.2009.06.016 19619488
MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9–26.19619488 10.1016/j.devcel.2009.06.016
40. Schunk SJ Floege J Fliser D Speer T WNT-β-catenin signalling—a versatile player in kidney injury and repair Nat Rev Nephrol 2021 17 172 184 10.1038/s41581-020-00343-w 32989282
Schunk SJ, Floege J, Fliser D, Speer T. WNT-β-catenin signalling—a versatile player in kidney injury and repair. Nat Rev Nephrol. 2021;17:172–84.32989282 10.1038/s41581-020-00343-w
41. Lee R Li J Li J Wu CJ Jiang S Hsu WH Chakravarti D Chen P LaBella KA Li J Synthetic essentiality of tryptophan 2,3-dioxygenase 2 in APC-mutated colorectal cancer Cancer Discov 2022 12 1702 1717 10.1158/2159-8290.CD-21-0680 35537038
Lee R, Li J, Li J, Wu CJ, Jiang S, Hsu WH, Chakravarti D, Chen P, LaBella KA, Li J, et al. Synthetic essentiality of tryptophan 2,3-dioxygenase 2 in APC-mutated colorectal cancer. Cancer Discov. 2022;12:1702–17.35537038 10.1158/2159-8290.CD-21-0680
42. Tomita H Yamada Y Oyama T Hata K Hirose Y Hara A Kunisada T Sugiyama Y Adachi Y Linhart H Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway Cancer Res 2007 67 4079 4087 10.1158/0008-5472.CAN-06-4025 17483318
Tomita H, Yamada Y, Oyama T, Hata K, Hirose Y, Hara A, Kunisada T, Sugiyama Y, Adachi Y, Linhart H, et al. Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway. Cancer Res. 2007;67:4079–87.17483318 10.1158/0008-5472.CAN-06-4025
43. Cruciat CM Niehrs C Secreted and transmembrane Wnt inhibitors and activators Cold Spring Harb Perspect Biol 2013 5 a015081 10.1101/cshperspect.a015081 23085770
Cruciat CM, Niehrs C. Secreted and transmembrane Wnt inhibitors and activators. Cold Spring Harb Perspect Biol. 2013;5: a015081.23085770 10.1101/cshperspect.a015081
44. Oshima T Abe M Asano J Hara T Kitazoe K Sekimoto E Tanaka Y Shibata H Hashimoto T Ozaki S Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2 Blood 2005 106 3160 3165 10.1182/blood-2004-12-4940 16030194
Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005;106:3160–5.16030194 10.1182/blood-2004-12-4940
45. Wang Y Zheng L Shang W Yang Z Li T Liu F Shao W Lv L Chai L Qu L Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer Cell Death Differ 2022 29 2190 2202 10.1038/s41418-022-01008-w 35534546
Wang Y, Zheng L, Shang W, Yang Z, Li T, Liu F, Shao W, Lv L, Chai L, Qu L, et al. Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer. Cell Death Differ. 2022;29:2190–202.35534546 10.1038/s41418-022-01008-w
46. Wu Q Ma J Wei J Meng W Wang Y Shi M lncRNA SNHG11 promotes gastric cancer progression by activating the Wnt/β-catenin pathway and oncogenic autophagy Mol Ther 2021 29 1258 1278 10.1016/j.ymthe.2020.10.011 33068778
Wu Q, Ma J, Wei J, Meng W, Wang Y, Shi M. lncRNA SNHG11 promotes gastric cancer progression by activating the Wnt/β-catenin pathway and oncogenic autophagy. Mol Ther. 2021;29:1258–78.33068778 10.1016/j.ymthe.2020.10.011
47. Zang X Jiang J Gu J Chen Y Wang M Zhang Y Fu M Shi H Cai H Qian H Circular RNA EIF4G3 suppresses gastric cancer progression through inhibition of β-catenin by promoting δ-catenin ubiquitin degradation and upregulating SIK1 Mol Cancer 2022 21 141 10.1186/s12943-022-01606-9 35780119
Zang X, Jiang J, Gu J, Chen Y, Wang M, Zhang Y, Fu M, Shi H, Cai H, Qian H, et al. Circular RNA EIF4G3 suppresses gastric cancer progression through inhibition of β-catenin by promoting δ-catenin ubiquitin degradation and upregulating SIK1. Mol Cancer. 2022;21:141.35780119 10.1186/s12943-022-01606-9
48. Xu C Xu Z Zhang Y Evert M Calvisi DF Chen X β-Catenin signaling in hepatocellular carcinoma J Clin Invest 2022 132 e154515 10.1172/JCI154515 35166233
Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. β-Catenin signaling in hepatocellular carcinoma. J Clin Invest. 2022;132: e154515.35166233 10.1172/JCI154515
49. Calderaro J Ziol M Paradis V Zucman-Rossi J Molecular and histological correlations in liver cancer J Hepatol 2019 71 616 630 10.1016/j.jhep.2019.06.001 31195064
Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71:616–30.31195064 10.1016/j.jhep.2019.06.001
50. Lin XH Liu HH Hsu SJ Zhang R Chen J Chen J Gao DM Cui JF Ren ZG Chen RX Norepinephrine-stimulated HSCs secrete sFRP1 to promote HCC progression following chronic stress via augmentation of a Wnt16B/β-catenin positive feedback loop J Exp Clin Cancer Res 2020 39 64 10.1186/s13046-020-01568-0 32293507
Lin XH, Liu HH, Hsu SJ, Zhang R, Chen J, Chen J, Gao DM, Cui JF, Ren ZG, Chen RX. Norepinephrine-stimulated HSCs secrete sFRP1 to promote HCC progression following chronic stress via augmentation of a Wnt16B/β-catenin positive feedback loop. J Exp Clin Cancer Res. 2020;39:64.32293507 10.1186/s13046-020-01568-0
51. Quan H Zhou F Nie D Chen Q Cai X Shan X Zhou Z Chen K Huang A Li S Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial–mesenchymal transition Oncogene 2014 33 2826 2835 10.1038/onc.2013.225 23770846
Quan H, Zhou F, Nie D, Chen Q, Cai X, Shan X, Zhou Z, Chen K, Huang A, Li S, et al. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial–mesenchymal transition. Oncogene. 2014;33:2826–35.23770846 10.1038/onc.2013.225
52. Shih YL Hsieh CB Lai HC Yan MD Hsieh TY Chao YC Lin YW SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway Int J Cancer 2007 121 1028 1035 10.1002/ijc.22750 17443492
Shih YL, Hsieh CB, Lai HC, Yan MD, Hsieh TY, Chao YC, Lin YW. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer. 2007;121:1028–35.17443492 10.1002/ijc.22750
53. Chen L Li M Li Q Wang CJ Xie SQ DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway Mol Cancer 2013 12 157 10.1186/1476-4598-12-157 24325363
Chen L, Li M, Li Q, Wang CJ, Xie SQ. DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway. Mol Cancer. 2013;12:157.24325363 10.1186/1476-4598-12-157
54. Yang RH Qin J Cao JL Zhang MZ Li YY Wang MQ Fang D Xie SQ Dickkopf-1 drives tumor immune evasion by inducing PD-L1 expression in hepatocellular carcinoma Biochem Pharmacol 2023 208 115378 10.1016/j.bcp.2022.115378 36513141
Yang RH, Qin J, Cao JL, Zhang MZ, Li YY, Wang MQ, Fang D, Xie SQ. Dickkopf-1 drives tumor immune evasion by inducing PD-L1 expression in hepatocellular carcinoma. Biochem Pharmacol. 2023;208: 115378.36513141 10.1016/j.bcp.2022.115378
55. Du W Menjivar RE Donahue KL Kadiyala P Velez-Delgado A Brown KL Watkoske HR He X Carpenter ES Angeles CV WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer J Exp Med 2023 220 e20220503 10.1084/jem.20220503 36239683
Du W, Menjivar RE, Donahue KL, Kadiyala P, Velez-Delgado A, Brown KL, Watkoske HR, He X, Carpenter ES, Angeles CV, et al. WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer. J Exp Med. 2023;220: e20220503.36239683 10.1084/jem.20220503
56. Huang Y Zhang R Lyu H Xiao S Guo D Chen XZ Zhou C Tang J LncRNAs as nodes for the cross-talk between autophagy and Wnt signaling in pancreatic cancer drug resistance Int J Biol Sci 2024 20 2698 2726 10.7150/ijbs.91832 38725864
Huang Y, Zhang R, Lyu H, Xiao S, Guo D, Chen XZ, Zhou C, Tang J. LncRNAs as nodes for the cross-talk between autophagy and Wnt signaling in pancreatic cancer drug resistance. Int J Biol Sci. 2024;20:2698–726.38725864 10.7150/ijbs.91832
57. Ni WJ Xie F Leng XM Terminus-associated Non-coding RNAs: trash or treasure? Front Genet 2020 11 552444 10.3389/fgene.2020.552444 33101379
Ni WJ, Xie F, Leng XM. Terminus-associated Non-coding RNAs: trash or treasure? Front Genet. 2020;11: 552444.33101379 10.3389/fgene.2020.552444
58. Chen X Sun Y Cai R Wang G Shu X Pang W Long noncoding RNA: multiple players in gene expression BMB Rep 2018 51 280 289 10.5483/BMBRep.2018.51.6.025 29636120
Chen X, Sun Y, Cai R, Wang G, Shu X, Pang W. Long noncoding RNA: multiple players in gene expression. BMB Rep. 2018;51:280–9.29636120 10.5483/BMBRep.2018.51.6.025
59. Ponting CP Oliver PL Reik W Evolution and functions of long noncoding RNAs Cell 2009 136 629 641 10.1016/j.cell.2009.02.006 19239885
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629–41.19239885 10.1016/j.cell.2009.02.006
60. Herman AB Tsitsipatis D Gorospe M Integrated lncRNA function upon genomic and epigenomic regulation Mol Cell 2022 82 2252 2266 10.1016/j.molcel.2022.05.027 35714586
Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022;82:2252–66.35714586 10.1016/j.molcel.2022.05.027
61. Tan YT Lin JF Li T Li JJ Xu RH Ju HQ LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer Cancer Commun (Lond) 2021 41 109 120 10.1002/cac2.12108 33119215
Tan YT, Lin JF, Li T, Li JJ, Xu RH, Ju HQ. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond). 2021;41:109–20.33119215 10.1002/cac2.12108
62. Nojima T Proudfoot NJ Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics Nat Rev Mol Cell Biol 2022 23 389 406 10.1038/s41580-021-00447-6 35079163
Nojima T, Proudfoot NJ. Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics. Nat Rev Mol Cell Biol. 2022;23:389–406.35079163 10.1038/s41580-021-00447-6
63. Dahariya S Paddibhatla I Kumar S Raghuwanshi S Pallepati A Gutti RK Long non-coding RNA: classification, biogenesis and functions in blood cells Mol Immunol 2019 112 82 92 10.1016/j.molimm.2019.04.011 31079005
Dahariya S, Paddibhatla I, Kumar S, Raghuwanshi S, Pallepati A, Gutti RK. Long non-coding RNA: classification, biogenesis and functions in blood cells. Mol Immunol. 2019;112:82–92.31079005 10.1016/j.molimm.2019.04.011
64. Chen S Shen X Long noncoding RNAs: functions and mechanisms in colon cancer Mol Cancer 2020 19 167 10.1186/s12943-020-01287-2 33246471
Chen S, Shen X. Long noncoding RNAs: functions and mechanisms in colon cancer. Mol Cancer. 2020;19:167.33246471 10.1186/s12943-020-01287-2
65. Fang L Huang H Lv J Chen Z Lu C Jiang T Xu P Li Y Wang S Li B m5C-methylated lncRNA NR_033928 promotes gastric cancer proliferation by stabilizing GLS mRNA to promote glutamine metabolism reprogramming Cell Death Dis 2023 14 520 10.1038/s41419-023-06049-8 37582794
Fang L, Huang H, Lv J, Chen Z, Lu C, Jiang T, Xu P, Li Y, Wang S, Li B, et al. m5C-methylated lncRNA NR_033928 promotes gastric cancer proliferation by stabilizing GLS mRNA to promote glutamine metabolism reprogramming. Cell Death Dis. 2023;14:520.37582794 10.1038/s41419-023-06049-8
66. Ni W Yao S Zhou Y Liu Y Huang P Zhou A Liu J Che L Li J Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m(6)A reader YTHDF3 Mol Cancer 2019 18 143 10.1186/s12943-019-1079-y 31619268
Ni W, Yao S, Zhou Y, Liu Y, Huang P, Zhou A, Liu J, Che L, Li J. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m(6)A reader YTHDF3. Mol Cancer. 2019;18:143.31619268 10.1186/s12943-019-1079-y
67. Zhou Y Shao Y Hu W Zhang J Shi Y Kong X Jiang J A novel long noncoding RNA SP100-AS1 induces radioresistance of colorectal cancer via sponging miR-622 and stabilizing ATG3 Cell Death Differ 2023 30 111 124 10.1038/s41418-022-01049-1 35978049
Zhou Y, Shao Y, Hu W, Zhang J, Shi Y, Kong X, Jiang J. A novel long noncoding RNA SP100-AS1 induces radioresistance of colorectal cancer via sponging miR-622 and stabilizing ATG3. Cell Death Differ. 2023;30:111–24.35978049 10.1038/s41418-022-01049-1
68. Schmitz SU Grote P Herrmann BG Mechanisms of long noncoding RNA function in development and disease Cell Mol Life Sci 2016 73 2491 2509 10.1007/s00018-016-2174-5 27007508
Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2016;73:2491–509.27007508 10.1007/s00018-016-2174-5
69. Lu J Zhu D Zhang X Wang J Cao H Li L The crucial role of LncRNA MIR210HG involved in the regulation of human cancer and other disease Clin Transl Oncol 2023 25 137 150 10.1007/s12094-022-02943-3 36088513
Lu J, Zhu D, Zhang X, Wang J, Cao H, Li L. The crucial role of LncRNA MIR210HG involved in the regulation of human cancer and other disease. Clin Transl Oncol. 2023;25:137–50.36088513 10.1007/s12094-022-02943-3
70. Huang Y The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases J Cell Mol Med 2018 22 5768 5775 10.1111/jcmm.13866 30188595
Huang Y. The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med. 2018;22:5768–75.30188595 10.1111/jcmm.13866
71. Huarte M The emerging role of lncRNAs in cancer Nat Med 2015 21 1253 1261 10.1038/nm.3981 26540387
Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21:1253–61.26540387 10.1038/nm.3981
72. Guttman M Rinn JL Modular regulatory principles of large non-coding RNAs Nature 2012 482 339 346 10.1038/nature10887 22337053
Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012;482:339–46.22337053 10.1038/nature10887
73. Ma L Yan W Sun X Chen P Long noncoding RNA VPS9D1-AS1 promotes esophageal squamous cell carcinoma progression via the Wnt/β-catenin signaling pathway J Cancer 2021 12 6894 6904 10.7150/jca.54556 34659577
Ma L, Yan W, Sun X, Chen P. Long noncoding RNA VPS9D1-AS1 promotes esophageal squamous cell carcinoma progression via the Wnt/β-catenin signaling pathway. J Cancer. 2021;12:6894–904.34659577 10.7150/jca.54556
74. You BH Yoon JH Kang H Lee EK Lee SK Nam JW HERES, a lncRNA that regulates canonical and noncanonical Wnt signaling pathways via interaction with EZH2 Proc Natl Acad Sci USA 2019 116 24620 24629 10.1073/pnas.1912126116 31732666
You BH, Yoon JH, Kang H, Lee EK, Lee SK, Nam JW. HERES, a lncRNA that regulates canonical and noncanonical Wnt signaling pathways via interaction with EZH2. Proc Natl Acad Sci USA. 2019;116:24620–9.31732666 10.1073/pnas.1912126116
75. Han GH Lu KJ Wang P Ye J Ye YY Huang JX LncRNA SNHG16 predicts poor prognosis in ESCC and promotes cell proliferation and invasion by regulating Wnt/β-catenin signaling pathway Eur Rev Med Pharmacol Sci 2018 22 3795 3803 29949155
Han GH, Lu KJ, Wang P, Ye J, Ye YY, Huang JX. LncRNA SNHG16 predicts poor prognosis in ESCC and promotes cell proliferation and invasion by regulating Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22:3795–803.29949155
76. Ge XS Ma HJ Zheng XH Ruan HL Liao XY Xue WQ Chen YB Zhang Y Jia WH HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway Cancer Sci 2013 104 1675 1682 10.1111/cas.12296 24118380
Ge XS, Ma HJ, Zheng XH, Ruan HL, Liao XY, Xue WQ, Chen YB, Zhang Y, Jia WH. HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway. Cancer Sci. 2013;104:1675–82.24118380 10.1111/cas.12296
77. Li Y Chen B Jiang X Li Y Wang X Huang S Wu X Xiao Y Shi D Huang X A Wnt-induced lncRNA-DGCR5 splicing switch drives tumor-promoting inflammation in esophageal squamous cell carcinoma Cell Rep 2023 42 112542 10.1016/j.celrep.2023.112542 37210725
Li Y, Chen B, Jiang X, Li Y, Wang X, Huang S, Wu X, Xiao Y, Shi D, Huang X, et al. A Wnt-induced lncRNA-DGCR5 splicing switch drives tumor-promoting inflammation in esophageal squamous cell carcinoma. Cell Rep. 2023;42: 112542.37210725 10.1016/j.celrep.2023.112542
78. Lin Z Wan AH Sun L Liang H Niu Y Deng Y Yan S Wang QP Bu X Zhang X N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis Mol Ther 2023 31 517 534 10.1016/j.ymthe.2022.10.012 36307991
Lin Z, Wan AH, Sun L, Liang H, Niu Y, Deng Y, Yan S, Wang QP, Bu X, Zhang X, et al. N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis. Mol Ther. 2023;31:517–34.36307991 10.1016/j.ymthe.2022.10.012
79. Xie R Cheng L Huang M Huang L Chen Z Zhang Q Li H Lu J Wang H Zhou Q NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer Cancer Res 2023 83 1666 1683 10.1158/0008-5472.CAN-22-2233 36939377
Xie R, Cheng L, Huang M, Huang L, Chen Z, Zhang Q, Li H, Lu J, Wang H, Zhou Q, et al. NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer. Cancer Res. 2023;83:1666–83.36939377 10.1158/0008-5472.CAN-22-2233
80. Zhou T Li S Xiang D Liu J Sun W Cui X Ning B Li X Cheng Z Jiang W m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance Signal Transduct Target Ther 2020 5 296 10.1038/s41392-020-00299-0 33361765
Zhou T, Li S, Xiang D, Liu J, Sun W, Cui X, Ning B, Li X, Cheng Z, Jiang W, et al. m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance. Signal Transduct Target Ther. 2020;5:296.33361765 10.1038/s41392-020-00299-0
81. Wang F Zhu W Yang R Xie W Wang D LncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer via activating the Wnt/β-catenin pathway Mol Cell Biochem 2019 456 73 83 10.1007/s11010-018-03491-7 30635820
Wang F, Zhu W, Yang R, Xie W, Wang D. LncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer via activating the Wnt/β-catenin pathway. Mol Cell Biochem. 2019;456:73–83.30635820 10.1007/s11010-018-03491-7
82. Xu W He L Li Y Tan Y Zhang F Xu H Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/β-catenin signaling in gastric cancer cells Biosci Biotechnol Biochem 2018 82 456 465 10.1080/09168451.2018.1431518 29424266
Xu W, He L, Li Y, Tan Y, Zhang F, Xu H. Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/β-catenin signaling in gastric cancer cells. Biosci Biotechnol Biochem. 2018;82:456–65.29424266 10.1080/09168451.2018.1431518
83. Liu J Wang G Zhao J Liu X Zhang K Gong G Pan H Jiang Z LncRNA H19 promoted the epithelial to mesenchymal transition and metastasis in gastric cancer via activating Wnt/β-catenin signaling Dig Dis 2022 40 436 447 10.1159/000518627 34348271
Liu J, Wang G, Zhao J, Liu X, Zhang K, Gong G, Pan H, Jiang Z. LncRNA H19 promoted the epithelial to mesenchymal transition and metastasis in gastric cancer via activating Wnt/β-catenin signaling. Dig Dis. 2022;40:436–47.34348271 10.1159/000518627
84. Hua H Su T Han L Zhang L Huang Y Zhang N Yang M LINC01226 promotes gastric cancer progression through enhancing cytoplasm-to-nucleus translocation of STIP1 and stabilizing β-catenin protein Cancer Lett 2023 577 216436 10.1016/j.canlet.2023.216436 37806517
Hua H, Su T, Han L, Zhang L, Huang Y, Zhang N, Yang M. LINC01226 promotes gastric cancer progression through enhancing cytoplasm-to-nucleus translocation of STIP1 and stabilizing β-catenin protein. Cancer Lett. 2023;577: 216436.37806517 10.1016/j.canlet.2023.216436
85. Zhou C An N Cao C Wang G lncRNA HOXC-AS1 promotes gastric cancer via binding eIF4AIII by activating Wnt/β-catenin signaling J Gene Med 2020 22 e3202 10.1002/jgm.3202 32307743
Zhou C, An N, Cao C, Wang G. lncRNA HOXC-AS1 promotes gastric cancer via binding eIF4AIII by activating Wnt/β-catenin signaling. J Gene Med. 2020;22: e3202.32307743 10.1002/jgm.3202
86. Zhang Y Liu X Wang Y Lai S Wang Z Yang Y Liu W Wang H Tang B The m(6)A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathway Mol Cancer 2022 21 174 10.1186/s12943-022-01647-0 36056355
Zhang Y, Liu X, Wang Y, Lai S, Wang Z, Yang Y, Liu W, Wang H, Tang B. The m(6)A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathway. Mol Cancer. 2022;21:174.36056355 10.1186/s12943-022-01647-0
87. Yang XZ Cheng TT He QJ Lei ZY Chi J Tang Z Liao QX Zhang H Zeng LS Cui SZ LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway Mol Cancer 2018 17 126 10.1186/s12943-018-0874-1 30134915
Yang XZ, Cheng TT, He QJ, Lei ZY, Chi J, Tang Z, Liao QX, Zhang H, Zeng LS, Cui SZ. LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway. Mol Cancer. 2018;17:126.30134915 10.1186/s12943-018-0874-1
88. Peng C Li X Yu Y Chen J LncRNA GASL1 inhibits tumor growth in gastric carcinoma by inactivating the Wnt/β-catenin signaling pathway Exp Ther Med 2019 17 4039 4045 30988785
Peng C, Li X, Yu Y, Chen J. LncRNA GASL1 inhibits tumor growth in gastric carcinoma by inactivating the Wnt/β-catenin signaling pathway. Exp Ther Med. 2019;17:4039–45.30988785
89. Li Y Guo D Zhao Y Ren M Lu G Wang Y Zhang J Mi C He S Lu X Long non-coding RNA SNHG5 promotes human hepatocellular carcinoma progression by regulating miR-26a-5p/GSK3β signal pathway Cell Death Dis 2018 9 888 10.1038/s41419-018-0882-5 30166525
Li Y, Guo D, Zhao Y, Ren M, Lu G, Wang Y, Zhang J, Mi C, He S, Lu X. Long non-coding RNA SNHG5 promotes human hepatocellular carcinoma progression by regulating miR-26a-5p/GSK3β signal pathway. Cell Death Dis. 2018;9:888.30166525 10.1038/s41419-018-0882-5
90. Liu Q Yu X Yang M Li X Zhai X Lian Y Chen Z Fan Q Song L Li W A study of the mechanism of lncRNA-CR594175 in regulating proliferation and invasion of hepatocellular carcinoma cells in vivo and in vitro Infect Agent Cancer 2020 15 55 10.1186/s13027-020-00321-8 32983253
Liu Q, Yu X, Yang M, Li X, Zhai X, Lian Y, Chen Z, Fan Q, Song L, Li W. A study of the mechanism of lncRNA-CR594175 in regulating proliferation and invasion of hepatocellular carcinoma cells in vivo and in vitro. Infect Agent Cancer. 2020;15:55.32983253 10.1186/s13027-020-00321-8
91. Lei T Zhu X Zhu K Jia F Li S EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway Cancer Biol Ther 2019 20 1007 1016 10.1080/15384047.2019.1595276 30929558
Lei T, Zhu X, Zhu K, Jia F, Li S. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway. Cancer Biol Ther. 2019;20:1007–16.30929558 10.1080/15384047.2019.1595276
92. Zhang S Jiang M Cao H Xiong J Xu J CTB-193M12.5 promotes hepatocellular carcinoma progression via enhancing NSD1-mediated WNT10B/Wnt/β-catenin signaling activation J Hepatocell Carcinoma. 2022 9 553 569 10.2147/JHC.S365302 35698644
Zhang S, Jiang M, Cao H, Xiong J, Xu J. CTB-193M12.5 promotes hepatocellular carcinoma progression via enhancing NSD1-mediated WNT10B/Wnt/β-catenin signaling activation. J Hepatocell Carcinoma. 2022;9:553–69.35698644 10.2147/JHC.S365302
93. Qin M Meng Y Luo C He S Qin F Yin Y Huang J Zhao H Hu J Deng Z lncRNA PRR34-AS1 promotes HCC development via modulating Wnt/β-catenin pathway by absorbing miR-296-5p and upregulating E2F2 and SOX12 Mol Ther Nucleic Acids 2021 25 37 52 10.1016/j.omtn.2021.04.016 34168917
Qin M, Meng Y, Luo C, He S, Qin F, Yin Y, Huang J, Zhao H, Hu J, Deng Z, et al. lncRNA PRR34-AS1 promotes HCC development via modulating Wnt/β-catenin pathway by absorbing miR-296-5p and upregulating E2F2 and SOX12. Mol Ther Nucleic Acids. 2021;25:37–52.34168917 10.1016/j.omtn.2021.04.016
94. Liang W Shi C Hong W Li P Zhou X Fu W Lin L Zhang J Super-enhancer-driven lncRNA-DAW promotes liver cancer cell proliferation through activation of Wnt/β-catenin pathway Mol Ther Nucleic Acids 2021 26 1351 1363 10.1016/j.omtn.2021.10.028 34853732
Liang W, Shi C, Hong W, Li P, Zhou X, Fu W, Lin L, Zhang J. Super-enhancer-driven lncRNA-DAW promotes liver cancer cell proliferation through activation of Wnt/β-catenin pathway. Mol Ther Nucleic Acids. 2021;26:1351–63.34853732 10.1016/j.omtn.2021.10.028
95. Yan X Zhang D Wu W Wu S Qian J Hao Y Yan F Zhu P Wu J Huang G Mesenchymal stem cells promote hepatocarcinogenesis via lncRNA-MUF interaction with ANXA2 and miR-34a Cancer Res 2017 77 6704 6716 10.1158/0008-5472.CAN-17-1915 28947421
Yan X, Zhang D, Wu W, Wu S, Qian J, Hao Y, Yan F, Zhu P, Wu J, Huang G, et al. Mesenchymal stem cells promote hepatocarcinogenesis via lncRNA-MUF interaction with ANXA2 and miR-34a. Cancer Res. 2017;77:6704–16.28947421 10.1158/0008-5472.CAN-17-1915
96. Zhang S Xu J Cao H Jiang M Xiong J KB-68A7.1 inhibits hepatocellular carcinoma development through binding to NSD1 and suppressing Wnt/β-catenin signalling Front Oncol 2021 11 808291 10.3389/fonc.2021.808291 35127520
Zhang S, Xu J, Cao H, Jiang M, Xiong J. KB-68A7.1 inhibits hepatocellular carcinoma development through binding to NSD1 and suppressing Wnt/β-catenin signalling. Front Oncol. 2021;11:808291.35127520 10.3389/fonc.2021.808291
97. Liang WC Ren JL Wong CW Chan SO Waye MM Fu WM Zhang JF LncRNA-NEF antagonized epithelial to mesenchymal transition and cancer metastasis via cis-regulating FOXA2 and inactivating Wnt/β-catenin signaling Oncogene 2018 37 1445 1456 10.1038/s41388-017-0041-y 29311643
Liang WC, Ren JL, Wong CW, Chan SO, Waye MM, Fu WM, Zhang JF. LncRNA-NEF antagonized epithelial to mesenchymal transition and cancer metastasis via cis-regulating FOXA2 and inactivating Wnt/β-catenin signaling. Oncogene. 2018;37:1445–56.29311643 10.1038/s41388-017-0041-y
98. Zhou L Jiang J Huang Z Jin P Peng L Luo M Zhang Z Chen Y Xie N Gao W Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m(6)A-mediated degradation of STEAP3 mRNA Mol Cancer 2022 21 168 10.1186/s12943-022-01638-1 35986274
Zhou L, Jiang J, Huang Z, Jin P, Peng L, Luo M, Zhang Z, Chen Y, Xie N, Gao W, et al. Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m(6)A-mediated degradation of STEAP3 mRNA. Mol Cancer. 2022;21:168.35986274 10.1186/s12943-022-01638-1
99. Lu Y Zhao X Liu Q Li C Graves-Deal R Cao Z Singh B Franklin JL Wang J Hu H lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling Nat Med 2017 23 1331 1341 10.1038/nm.4424 29035371
Lu Y, Zhao X, Liu Q, Li C, Graves-Deal R, Cao Z, Singh B, Franklin JL, Wang J, Hu H, et al. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat Med. 2017;23:1331–41.29035371 10.1038/nm.4424
100. Qi Y Shan Y Li S Huang Y Guo Y Huang T Zhao X Jia L LncRNA LEF1-AS1/LEF1/FUT8 axis mediates colorectal cancer progression by regulating α1, 6-fucosylationvia Wnt/β-catenin pathway Dig Dis Sci 2022 67 2182 2194 10.1007/s10620-021-07051-w 34021424
Qi Y, Shan Y, Li S, Huang Y, Guo Y, Huang T, Zhao X, Jia L. LncRNA LEF1-AS1/LEF1/FUT8 axis mediates colorectal cancer progression by regulating α1, 6-fucosylationvia Wnt/β-catenin pathway. Dig Dis Sci. 2022;67:2182–94.34021424 10.1007/s10620-021-07051-w
101. Luo Y Huang S Wei J Zhou H Wang W Yang J Deng Q Wang H Fu Z Long noncoding RNA LINC01606 protects colon cancer cells from ferroptotic cell death and promotes stemness by SCD1-Wnt/β-catenin-TFE3 feedback loop signalling Clin Transl Med 2022 12 e752 10.1002/ctm2.752 35485210
Luo Y, Huang S, Wei J, Zhou H, Wang W, Yang J, Deng Q, Wang H, Fu Z. Long noncoding RNA LINC01606 protects colon cancer cells from ferroptotic cell death and promotes stemness by SCD1-Wnt/β-catenin-TFE3 feedback loop signalling. Clin Transl Med. 2022;12: e752.35485210 10.1002/ctm2.752
102. Ding D Li C Zhao T Li D Yang L Zhang B LncRNA H19/miR-29b-3p/PGRN axis promoted epithelial–mesenchymal transition of colorectal cancer cells by acting on Wnt signaling Mol Cells 2018 41 423 435 29754471
Ding D, Li C, Zhao T, Li D, Yang L, Zhang B. LncRNA H19/miR-29b-3p/PGRN axis promoted epithelial–mesenchymal transition of colorectal cancer cells by acting on Wnt signaling. Mol Cells. 2018;41:423–35.29754471
103. Yu J Han Z Sun Z Wang Y Zheng M Song C LncRNA SLCO4A1-AS1 facilitates growth and metastasis of colorectal cancer through β-catenin-dependent Wnt pathway J Exp Clin Cancer Res 2018 37 222 10.1186/s13046-018-0896-y 30201010
Yu J, Han Z, Sun Z, Wang Y, Zheng M, Song C. LncRNA SLCO4A1-AS1 facilitates growth and metastasis of colorectal cancer through β-catenin-dependent Wnt pathway. J Exp Clin Cancer Res. 2018;37:222.30201010 10.1186/s13046-018-0896-y
104. Duan W Kong X Li J Li P Zhao Y Liu T Binang HB Wang Y Du L Wang C LncRNA AC010789.1 promotes colorectal cancer progression by targeting microRNA-432–3p/ZEB1 axis and the Wnt/β-catenin signaling pathway Front Cell Dev Biol. 2020 8 565355 10.3389/fcell.2020.565355 33178684
Duan W, Kong X, Li J, Li P, Zhao Y, Liu T, Binang HB, Wang Y, Du L, Wang C. LncRNA AC010789.1 promotes colorectal cancer progression by targeting microRNA-432–3p/ZEB1 axis and the Wnt/β-catenin signaling pathway. Front Cell Dev Biol. 2020;8: 565355.33178684 10.3389/fcell.2020.565355
105. Han P Li JW Zhang BM Lv JC Li YM Gu XY Yu ZW Jia YH Bai XF Li L The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling Mol Cancer 2017 16 9 10.1186/s12943-017-0583-1 28086904
Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, Yu ZW, Jia YH, Bai XF, Li L, et al. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling. Mol Cancer. 2017;16:9.28086904 10.1186/s12943-017-0583-1
106. Xiao Z Qu Z Chen Z Fang Z Zhou K Huang Z Guo X Zhang Y LncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt/ß-catenin signaling pathway Cell Physiol Biochem 2018 46 1275 1285 10.1159/000489110 29680837
Xiao Z, Qu Z, Chen Z, Fang Z, Zhou K, Huang Z, Guo X, Zhang Y. LncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt/ß-catenin signaling pathway. Cell Physiol Biochem. 2018;46:1275–85.29680837 10.1159/000489110
107. Tang Z Tian W Long H Jiang S Zhao J Zhou J He Q Luo X Subcellular-targeted near-infrared-responsive nanomedicine with synergistic chemo-photothermal therapy against multidrug resistant cancer Mol Pharm 2022 19 4538 4551 10.1021/acs.molpharmaceut.1c00998 35311257
Tang Z, Tian W, Long H, Jiang S, Zhao J, Zhou J, He Q, Luo X. Subcellular-targeted near-infrared-responsive nanomedicine with synergistic chemo-photothermal therapy against multidrug resistant cancer. Mol Pharm. 2022;19:4538–51.35311257 10.1021/acs.molpharmaceut.1c00998
108. Liu H Li D Sun L Qin H Fan A Meng L Graves-Deal R Glass SE Franklin JL Liu Q Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m(6)A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression Mol Cancer 2022 21 74 10.1186/s12943-022-01555-3 35279145
Liu H, Li D, Sun L, Qin H, Fan A, Meng L, Graves-Deal R, Glass SE, Franklin JL, Liu Q, et al. Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m(6)A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression. Mol Cancer. 2022;21:74.35279145 10.1186/s12943-022-01555-3
109. Zhu Y Zhou B Hu X Ying S Zhou Q Xu W Feng L Hou T Wang X Zhu L LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability Clin Transl Med 2022 12 e703 10.1002/ctm2.703 35073459
Zhu Y, Zhou B, Hu X, Ying S, Zhou Q, Xu W, Feng L, Hou T, Wang X, Zhu L, et al. LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability. Clin Transl Med. 2022;12: e703.35073459 10.1002/ctm2.703
110. Zhou C Yi C Yi Y Qin W Yan Y Dong X Zhang X Huang Y Zhang R Wei J LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes Mol Cancer 2020 19 118 10.1186/s12943-020-01237-y 32727463
Zhou C, Yi C, Yi Y, Qin W, Yan Y, Dong X, Zhang X, Huang Y, Zhang R, Wei J, et al. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes. Mol Cancer. 2020;19:118.32727463 10.1186/s12943-020-01237-y
111. Lin C Wang Y Dong Y Lai S Wang L Weng S Zhang X N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway Biol Direct 2022 17 33 10.1186/s13062-022-00347-5 36397058
Lin C, Wang Y, Dong Y, Lai S, Wang L, Weng S, Zhang X. N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway. Biol Direct. 2022;17:33.36397058 10.1186/s13062-022-00347-5
112. Chen LJ Wu L Wang W Zhai LL Xiang F Li WB Tang ZG Long non-coding RNA 01614 hyperactivates WNT/β-catenin signaling to promote pancreatic cancer progression by suppressing GSK-3β Int J Oncol 2022 61 1 10.3892/ijo.2022.5406
Chen LJ, Wu L, Wang W, Zhai LL, Xiang F, Li WB, Tang ZG. Long non-coding RNA 01614 hyperactivates WNT/β-catenin signaling to promote pancreatic cancer progression by suppressing GSK-3β. Int J Oncol. 2022;61:1.10.3892/ijo.2022.5406
113. Shi C Zhang H Wang M Tian R Li X Feng Y Peng F Qin R OPA interacting protein 5 antisense RNA 1 expedites cell migration and invasion through FOXM1/ Wnt/β-catenin pathway in pancreatic cancer Dig Dis Sci 2022 67 915 924 10.1007/s10620-021-06919-1 33782807
Shi C, Zhang H, Wang M, Tian R, Li X, Feng Y, Peng F, Qin R. OPA interacting protein 5 antisense RNA 1 expedites cell migration and invasion through FOXM1/ Wnt/β-catenin pathway in pancreatic cancer. Dig Dis Sci. 2022;67:915–24.33782807 10.1007/s10620-021-06919-1
114. Zhou M Pan S Qin T Zhao C Yin T Gao Y Liu Y Zhang Z Shi Y Bai Y LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation J Exp Clin Cancer Res 2022 41 288 10.1186/s13046-022-02491-2 36171592
Zhou M, Pan S, Qin T, Zhao C, Yin T, Gao Y, Liu Y, Zhang Z, Shi Y, Bai Y, et al. LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation. J Exp Clin Cancer Res. 2022;41:288.36171592 10.1186/s13046-022-02491-2
115. Ling J Wang F Liu C Dong X Xue Y Jia X Song W Li Q FOXO1-regulated lncRNA LINC01197 inhibits pancreatic adenocarcinoma cell proliferation by restraining Wnt/β-catenin signaling J Exp Clin Cancer Res 2019 38 179 10.1186/s13046-019-1174-3 31027497
Ling J, Wang F, Liu C, Dong X, Xue Y, Jia X, Song W, Li Q. FOXO1-regulated lncRNA LINC01197 inhibits pancreatic adenocarcinoma cell proliferation by restraining Wnt/β-catenin signaling. J Exp Clin Cancer Res. 2019;38:179.31027497 10.1186/s13046-019-1174-3
116. Uttam V Rana MK Sharma U Singh K Jain A Circulating long non-coding RNA EWSAT1 acts as a liquid biopsy marker for esophageal squamous cell carcinoma: a pilot study Noncoding RNA Res 2024 9 1 11 10.1016/j.ncrna.2023.10.009 38028735
Uttam V, Rana MK, Sharma U, Singh K, Jain A. Circulating long non-coding RNA EWSAT1 acts as a liquid biopsy marker for esophageal squamous cell carcinoma: a pilot study. Noncoding RNA Res. 2024;9:1–11.38028735 10.1016/j.ncrna.2023.10.009
117. Costa-Pinheiro P Montezuma D Henrique R Jerónimo C Diagnostic and prognostic epigenetic biomarkers in cancer Epigenomics 2015 7 1003 1015 10.2217/epi.15.56 26479312
Costa-Pinheiro P, Montezuma D, Henrique R, Jerónimo C. Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics. 2015;7:1003–15.26479312 10.2217/epi.15.56
118. Davalos V Esteller M Cancer epigenetics in clinical practice CA Cancer J Clin 2023 73 376 424 10.3322/caac.21765 36512337
Davalos V, Esteller M. Cancer epigenetics in clinical practice. CA Cancer J Clin. 2023;73:376–424.36512337 10.3322/caac.21765
119. Feinberg AP Levchenko A Epigenetics as a mediator of plasticity in cancer Science 2023 379 eaaw3835 10.1126/science.aaw3835 36758093
Feinberg AP, Levchenko A. Epigenetics as a mediator of plasticity in cancer. Science. 2023;379:eaaw3835.36758093 10.1126/science.aaw3835
120. Thandapani P Super-enhancers in cancer Pharmacol Ther 2019 199 129 138 10.1016/j.pharmthera.2019.02.014 30885876
Thandapani P. Super-enhancers in cancer. Pharmacol Ther. 2019;199:129–38.30885876 10.1016/j.pharmthera.2019.02.014
121. Ames BN Shigenaga MK Gold LS DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis Environ Health Perspect 1993 101 Suppl 5 35 44 10.1289/ehp.93101s535 8013423
Ames BN, Shigenaga MK, Gold LS. DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis. Environ Health Perspect. 1993;101(Suppl 5):35–44.8013423 10.1289/ehp.93101s535
122. Scott TL Rangaswamy S Wicker CA Izumi T Repair of oxidative DNA damage and cancer: recent progress in DNA base excision repair Antioxid Redox Signal 2014 20 708 726 10.1089/ars.2013.5529 23901781
Scott TL, Rangaswamy S, Wicker CA, Izumi T. Repair of oxidative DNA damage and cancer: recent progress in DNA base excision repair. Antioxid Redox Signal. 2014;20:708–26.23901781 10.1089/ars.2013.5529
123. Pirozzi CJ Yan H The implications of IDH mutations for cancer development and therapy Nat Rev Clin Oncol 2021 18 645 661 10.1038/s41571-021-00521-0 34131315
Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol. 2021;18:645–61.34131315 10.1038/s41571-021-00521-0
